[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1318
1. Helmbach H, Rossmann E, Kern MA, Schadendorf D: Drug-resistance in human melanoma. Int J Cancer; 2001 Sep 1;93(5):617-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-resistance in human melanoma.
  • Advanced malignant melanoma has a poor prognosis since chemotherapy is mostly ineffective due in part to the intrinsic and/or extrinsic resistance of melanoma cells to systemic treatment with anti-neoplastic agents.
  • The relevance of well-analyzed drug-resistance mechanisms, e.g., intracellular/extracellular transport and induction of certain enzyme systems, is reviewed.
  • Most anti-cancer drugs kill susceptible cells through induction of apoptosis.
  • Therefore, it appears that differences in the apoptotic pathways which lead to apoptotic deficiency may account for the ability of some tumor cells to resist drug therapy.
  • Human melanomas, which are characteristically drug-resistant, are more likely to have altered apoptotic pathways and fewer pro-apoptotic molecules.
  • Tumor cells with these characteristics are seldom sensitive to drugs.
  • Thus, apoptosis and apoptotic deficiency should be analyzed to better clarify the mechanisms of melanoma resistance.
  • [MeSH-major] Apoptosis. DNA Repair / physiology. Drug Resistance, Neoplasm / physiology. Melanoma / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11477569.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


2. Dimitrov BD, Rachkova MI, Atanassova PA: Cyclic patterns of incidence rate for skin malignant melanoma: association with heliogeophysical activity. J Zhejiang Univ Sci B; 2008 Jun;9(6):489-95
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic patterns of incidence rate for skin malignant melanoma: association with heliogeophysical activity.
  • BACKGROUND: Our previous studies revealed cyclicity in the incidence rate of skin malignant melanoma (SMM; ICD9, Dx:172) in the Czech Republic (period T=7.50-7.63 years), UK (T=11.00 years) and Bulgaria (T=12.20 years).
  • Incidences compared with the sunspot index Rz (lag-period dT=+2, +4, +6, +10 or +12 years) have indicated that maximal rates are most likely to appear on descending slopes of the 11-year solar cycle, i.e., out of phase.
  • METHODS: Annual incidences of SMM from 5 countries (Czech Republic, UK, Bulgaria, USA and Canada) over various time spans during the years 1964-1992 were analyzed and their correlations with cyclic Rz (sunspot number) and aa (planetary geomagnetic activity) indices were summarized.
  • The association of SMM for USA and Canada with Rz (dT=+6 and +7 years, respectively) and aa (dT=-10 and +9 years, respectively) was described.
  • Possible interactions of cyclic non-photic influences (UV irradiation, Schumann resonance signal, low-frequency geomagnetic fluctuations) with brain waves absorbance, neuronal calcium dynamics, neuro-endocrine axis modulation, melatonin/serotonin disbalance and skin neuro-immunity impairment as likely causal pathways in melanoma appearance, were also discussed.
  • CONCLUSION: The above findings on cyclicity and temporal association of SMM with cyclic environmental factors could not only allow for better forecasting models but also lead to a better understanding of melanoma aetiology.
  • [MeSH-major] Melanoma / epidemiology. Periodicity. Skin Neoplasms / epidemiology. Solar Activity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomed Pharmacother. 2003 Oct;57 Suppl 1:19s-23s [14572672.001]
  • [Cites] Lancet. 1978 Apr 8;1(8067):759-60 [76759.001]
  • [Cites] Lancet. 1978 Jul 1;2(8079):38 [78226.001]
  • [Cites] Int J Biometeorol. 1993 May;37(2):68-71 [8330942.001]
  • [Cites] Folia Med (Plovdiv). 1998;40(3B Suppl 3):66-71 [10205998.001]
  • [Cites] Biomed Pharmacother. 2004 Oct;58 Suppl 1:S150-87 [15754855.001]
  • [Cites] Breast Cancer Res Treat. 2008 Apr;108(3):339-50 [17541739.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 1:S1-4 [16275476.001]
  • [Cites] Environ Res. 2006 May;101(1):123-31 [16290819.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):431-5 [16648048.001]
  • [Cites] J Zhejiang Univ Sci B. 2007 Sep;8(9):609-11 [17726739.001]
  • [Cites] Exp Neurol. 2008 Mar;210(1):274-9 [18076878.001]
  • [Cites] Dermatology. 2005;211(3):199-208 [16205064.001]
  • (PMID = 18543403.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2408703
  •  go-up   go-down


3. Cheng SL, Huang Liu R, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ: Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull; 2006 Apr;29(4):655-69
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells.
  • Kojic acid is a natural product and normally used as a food additive and preservative, a skin-whitening agent in cosmetics, a plant growth regulator and a chemical intermediate.
  • Using DNA microarray technology, the overall biological effects of kojic acid on the gene expression profiling of a human skin A375 malignant melanoma cells were examined.
  • After treatment with kojic acid, a total of 361 differentially expressed genes were distinctively changed with 136 up-regulated genes and 225 down-regulated genes.
  • Seven down-regulated genes of APOBEC1, ARHGEF16, CD22, FGFR3, GALNT1, UNC5C and ZNF146 that were typically validated by the real-time quantitative PCR (RT-qPCR) analysis technology showed to be the tumor suppressor genes in melanoma cancer cells.
  • Thus, microarray technology coupled with RT-qPCR offered a high throughput method to explore the number of differentially expressed genes responding to kojic acid and their biological functions, and led to more understanding of kojic acid effects on skin cancer therapy and related side effects.
  • Moreover, the differentially expressed genes may become useful markers of skin malignant melanoma for further diagnostic and therapeutic applications.
  • [MeSH-major] Antioxidants / toxicity. Melanoma / genetics. Pyrones / toxicity. Skin Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Computational Biology. Gene Amplification. Gene Expression / drug effects. Gene Expression Profiling. Genetic Markers. Humans. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. KOJIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595896.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Genetic Markers; 0 / Pyrones; 0 / RNA, Neoplasm; 6K23F1TT52 / kojic acid
  •  go-up   go-down


Advertisement
4. Patonay P, Naszály A, Mayer A, Pócza K, Kovács L: [Radio-chemotherapy for non-resectable primary esophageal malignant melanoma]. Magy Onkol; 2004;48(4):303-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radio-chemotherapy for non-resectable primary esophageal malignant melanoma].
  • [Transliterated title] Irreszekábilis elsôdleges nyelôcsô melanoma malignum radiokemoterápiája.
  • AIM: to demonstrate the simultaneous radio-chemotherapy of primary esophageal malignant melanoma on the basis of one case.
  • PATIENT AND METHODS: 68-years-old male patient with malignant melanoma in middle part of the esophagus.
  • The therapy was started with intraluminal high-dose-rate afterloading brachytherapy for the recanalisation of the esophagus (8 Gy in 0.5 cm deep), followed by percutaneous megavolt therapy two weeks after the last HDR AL session (50 Gy total dose, 5 x 2 Gy/week fractions for 5 week, 3D conformal planning).
  • The chemotherapy was started simultaneously with the percutaneous megavolt irradiation (three courses of Cisplatin-5-Fluorouracil combination, repeated in four-week intervals).
  • After the radio-chemotherapy a supraclavicular metastasis was verified, so the radio-chemotherapy was followed with megavolt therapy of the metastasis at 30 Gy dose (5 x 2 Gy/week fractions), and chemotherapy (Cisplatin-Dacarbazine combination in 6-session, four-week intervals) and after them immunotherapy was started.
  • After the beginning of the radio-chemotherapy the swallow function was good for 16 months, and 18 months after the beginning of radio-chemotherapy the patient died due to pulmonary and hepatic dissemination.
  • CONCLUSION: Radio-chemotherapy of esophageal malignant melanoma has favorable palliative effect with acceptable quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Melanoma / drug therapy. Melanoma / radiotherapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Palliative Care / methods. Quality of Life. Radiotherapy Dosage. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655575.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Hauschild A, Volkenandt M, Garbe C: [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries]. Dtsch Med Wochenschr; 2000 Oct 20;125(42):1272-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries].
  • [Transliterated title] Adjuvante medikamentöse Therapie des malignen Melanoms. Aktueller Wissensstand und derzeitige Multicenterstudien in den deutschsprachigen Ländern.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Europe. Humans. Multicenter Studies as Topic. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11098240.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 33
  •  go-up   go-down


6. Mula V, Mandal A, Britton E, Shanker VS: Direct bony invasion of malignant melanoma. Indian J Orthop; 2009 Oct;43(4):420-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct bony invasion of malignant melanoma.
  • Malignant melanoma is known to spread by local extention, by the lymphatics by the blood stream.
  • Direct invasion of the bone from a cutaneous melanoma is unknown.
  • Histopathology diagnosed the lesion as locally advanced malignant melanoma.
  • Radiological investigations by X-ray and magnetic resonance imaging revealed malignant infiltration of the tibia in its mid and lower third with two soft tissue metastatic masses adjacent.
  • Histology following amputation confirmed malignant melanoma with cranial resection margin involvement.
  • She underwent a further above-knee amputation followed by chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orthopedics. 2001 Mar;24(3):225, 307-8 [11300284.001]
  • [Cites] J Bone Joint Surg Am. 2001 Nov;83-A(11):1713-7 [11701796.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1780-4 [11100057.001]
  • [Cites] J Laryngol Otol. 2000 May;114(5):378-80 [10912271.001]
  • [Cites] Can J Surg. 2000 Apr;43(2):137-9 [10812349.001]
  • [Cites] J Hand Surg Am. 2000 Mar;25(2):365-9 [10722831.001]
  • [Cites] Int J Clin Oncol. 2007 Aug;12(4):305-8 [17701013.001]
  • [Cites] Ear Nose Throat J. 2007 Jul;86(7):388-90 [17702316.001]
  • [Cites] J Cutan Med Surg. 2006 Jan-Feb;10(1):36-40 [17241571.001]
  • [Cites] Europace. 2006 Jul;8(7):545-8 [16798769.001]
  • [Cites] Am Surg. 2006 Jan;72(1):98-100 [16494196.001]
  • [Cites] J Hand Surg Am. 2005 May;30(3):615-9 [15925176.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • [Cites] Arch Pathol Lab Med. 1999 Feb;123(2):163-6 [10050793.001]
  • [Cites] J Laryngol Otol. 2004 May;118(5):382-4 [15165318.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):194-200 [15043888.001]
  • [Cites] Clin Nucl Med. 2003 Dec;28(12):961-5 [14663316.001]
  • [Cites] Mol Imaging Biol. 2002 Oct;4(5):359-62 [14537111.001]
  • [Cites] Rom J Gastroenterol. 2002 Mar;11(1):53-6 [12096315.001]
  • [Cites] J Hand Surg Am. 2000 Nov;25(6):1169-72 [11119681.001]
  • (PMID = 19838397.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2762569
  • [Keywords] NOTNLM ; Bone tumor / direct invasion / malignant melanoma / metastatic melanoma
  •  go-up   go-down


7. Hauschild A, Lischner S, Christophers E: [Surgical and adjuvant drug therapy in head and neck cutaneous melanoma]. Laryngorhinootologie; 2000 Jul;79(7):428-33
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical and adjuvant drug therapy in head and neck cutaneous melanoma].
  • [Transliterated title] Operative und adjuvante medikamentöse Therapie des kutanen Melanoms im Kopf-Hals-Bereich.
  • The rapid incidence rise of cutaneous melanoma resulted in an increasing interest in this particular tumor.
  • During the last years public prevention campaigns enlarged the awareness of melanoma, subsequently as a direct effect the mean tumor thickness of melanoma, the most predictable prognostic factor, decreased.
  • Moreover, the biology of melanoma initiation and metastasis has been studied extensively with special interest in molecular biology.
  • Controlled clinical studies answered several critical questions in respect to the standard care of surgery in melanoma.
  • Yet, the guidelines for the surgical treatment of head and neck melanoma are in accordance to that of other localisations with reduced safety margins around the primary tumor.
  • Moreover, ELND has been given up by most melanoma centers, since it is known that prospective-randomized trials were not able to demonstrate an increase of overall survival for patients with ELND compared with untreated patients.
  • Instead of this potentially aggressive treatment modality the examination of the first draining regional lymph node, sentinel node biopsy (SNB), has been introduced some years ago.
  • Recently, a large clinical trial demonstrated that the SNB status reflects the most valuable prognostic factor for primary melanoma known so far.
  • First studies in head and neck melanoma figured out that this technique is more complex in this special localisation, but produced comparable results.
  • Systemic adjuvant (prophylactic) therapy of high-risk melanoma should preferentially be applied within controlled clinical trials.
  • Most attractive candidates for an effective treatment are interferons.
  • Several studies ruled out that interferon alpha-treated melanoma patients demonstrate an extended disease-free survival.
  • Adjuvant chemotherapy has not shown a clinically relevant benefit.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Dacarbazine / therapeutic use. Humans. Interferons / therapeutic use. Lymph Node Excision. Sentinel Lymph Node Biopsy. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005097.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 9008-11-1 / Interferons
  • [Number-of-references] 30
  •  go-up   go-down


8. Fauzdar S, Rao DD, Arthanari KK, Krishnan G, Naikmasur VG, Revanappa MM: Malignant melanoma of the mandibular gingiva. Rare Tumors; 2010;2(2):e25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the mandibular gingiva.
  • Oral malignant melanoma is an infrequent neoplasia making up less than 1% of all melanomas, which exhibits much more aggressive behavior than those found on the skin.
  • We present an aggressive case of oral malignant melanoma located on the mandibular gingiva in a 24-year-old male patient, who developed metastases to not only the regional lymph nodes but also the lungs and liver.
  • The advanced stage of the disease contraindicated any surgical intervention and palliative chemotherapy was planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139827.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994515
  • [Keywords] NOTNLM ; melanoma / mucosal melanoma. / oral malignant melanoma / oral mucosa / oral pigmentation
  •  go-up   go-down


9. Grubisić-Cabo F, Vrdoljak E: Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. Med Oncol; 2006;23(1):121-4
Hazardous Substances Data Bank. Gemfibrozil .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy.
  • A well-known side effect of chemotherapy, covering a wide range of drugs, is drug-induced hepatitis.
  • We are reporting on a 61-yr-old female patient whose malignant melanoma had been surgically removed, and on whom adjuvant therapy with interferon alfa 2b was initiated.
  • After the patient was started on interferon alfa therapy, continuously increasing values of triglyceride were measured.
  • Therefore, 3 mo after the introduction of adjuvant therapy, gemfibrozil was prescribed at a dose of 600 mg per day.
  • Within a few days after the patient had been taking this combined therapy, the clinical and laboratory values of drug-induced hepatitis developed.
  • Soon after discontinuance of treatment by both drugs, the signs and symptoms of hepatitis disappeared.
  • Adjuvant interferon therapy was not continued afterward owing to the patient's wish.
  • We do not know if the hepatitis was the side effect to gemfibrozil alone, or the side effect was a result of an interaction between the two drugs.
  • Our intention in this article is to point out that prescription of any drugs, especially new ones, should be balanced and carefully monitored because of possible side effects.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Chemical and Drug Induced Liver Injury / etiology. Gemfibrozil / adverse effects. Hypolipidemic Agents / adverse effects. Interferon-alpha / adverse effects. Melanoma / drug therapy
  • [MeSH-minor] Drug Interactions. Female. Humans. Middle Aged. Recombinant Proteins

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1992 Oct 31;78(5):353-5 [1494811.001]
  • [Cites] Biochem Pharmacol. 1995 May 11;49(9):1213-21 [7763302.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Jan;142(1):143-50 [9007043.001]
  • [Cites] Med J Aust. 1956 Jun 30;43(26):1082-7 [13347440.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17 ):3703-18 [12202672.001]
  • [Cites] Diabetes Metab. 2001 Feb;27(1):66-8 [11240449.001]
  • [Cites] N Engl J Med. 1999 Aug 5;341(6):410-8 [10438259.001]
  • [Cites] Nephrol Dial Transplant. 2001 Dec;16(12):2418-9 [11733637.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):207-10 [9521434.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):53-61 [14665609.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2274-80 [3179941.001]
  • [Cites] Cancer. 1993 May 15;71(10):2995-3005 [8490827.001]
  • [Cites] J Clin Oncol. 1996 Jan;14 (1):7-17 [8558223.001]
  • [Cites] JAMA. 2001 Jan 24-31;285(4):437-43 [11242428.001]
  • [Cites] Ann Pharmacother. 2004 Oct;38(10):1655-9 [15304625.001]
  • (PMID = 16645237.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypolipidemic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b; Q8X02027X3 / Gemfibrozil
  •  go-up   go-down


10. Wong SF, Jakowatz JG, Taheri R: Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother; 2004 Oct;38(10):1655-9
MedlinePlus Health Information. consumer health - Triglycerides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
  • OBJECTIVE: To describe 3 cases of hypertriglyceridemia associated with the use of interferon alfa (IFN-alpha) for the treatment of malignant melanoma and propose a management plan for dyslipidemia associated with interferon therapy.
  • CASE SUMMARIES: Three case reports of hypertriglyceridemia with or without elevation of total cholesterol level associated with the use of adjuvant IFN-alpha for the treatment of malignant melanoma are described.
  • These patients received IFN-alpha-based adjuvant therapy with doses ranging from 5-20 million units/m(2) for 1-2 years' duration.
  • DISCUSSION: Based on our case reports and published data, hypertriglyceridemia is more frequently associated with longer duration of interferon therapy, although the time of onset is not clearly defined.
  • Lifestyle modifications should be encouraged in patients who develop dyslipidemia, and drug treatment should be considered.
  • If drug therapy is indicated, fibric acid derivatives should be considered as first-line therapy.
  • Even at lower doses, this class of drug seems to be effective in managing severe triglyceride elevations in these patients.
  • CONCLUSIONS: Hypertriglyceridemia is a rare but potentially severe adverse consequence of interferon therapy.
  • Patients with malignant melanoma who develop dyslipidemia while receiving interferon should be considered for antidyslipidemic management.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hypertriglyceridemia / chemically induced. Hypolipidemic Agents / therapeutic use. Interferon-alpha / adverse effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15304625.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypolipidemic Agents; 0 / Interferon-alpha
  •  go-up   go-down


11. Billich A: Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs; 2002 May;3(5):698-707
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymosin alpha1 (Talpha1), a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement, was originally developed by Alpha 1 Biomedicals for the treatment of hepatitis B virus (HBV) infection.
  • SciClone developed and launched Talpha1, under the trade name Zadaxin, for the treatment of HBV and hepatitis C virus (HCV) infections.
  • The drug is also being developed for the treatment of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS and malignant melanoma.
  • Talpha1 is able to potentiate the action of cytokines and also reduce the hematological toxicity of cytotoxic drug therapy (cyclophosphamide-, 5-fluorouracil-, dacarbazine- or ifosfamide-based regimens).
  • Talpha1 has been launched in Argentina, China, Peru, the Philippines and Singapore for the treatment of chronic HBV infection.
  • The product subsequently received expanded approval for the treatment of both HBV and HCV infection in Argentina.
  • In March 2000, approval for treatment of HBV infection was granted in Thailand, Laos and Malta.
  • In September 2000, SciClone announced that approval had been expanded to include the treatment of HCV infection as well as the previously approved HBV indication in both Peru and Sri Lanka.
  • In January 1999, SciClone received approval for Talpha1 in Venezuela for the treatment of HBV and HCV infection.
  • The drug was approved in South Korea in April 2000, as an influenza vaccine adjuvant and this was expected to be expanded to indude use for treatment of both HBV and HCV infections.
  • In July 2001, it was approved in In September and October 2000, SciClone was granted patents in Mexico and Canada, respectively, for the use of Talpha1 for the treatment of HCV infection.
  • In June 2000, SciClone was issued a Notice of Allowance by the US Patent and Trademark Office for use of Talpha1 in the treatment of HBV infection.
  • The patent gave the Philippines as an adjuvant to chemotherapy for the treatment of various cancers.
  • SciClone exclusive composition-of-matter rights to several families of Talpha1 analogs that could have proprietary therapeutic or biologic distinctions from Talpha1.
  • The company was issued US patents covering the use of Talpha1 for the treatment of HCV infection in August 1998 and the treatment of HBV infection in September 1999.
  • In April 1999, SciClone received allowance of a patent from the EPO covering the use of Talpha1 in small cell and non-small cell lung cancer.
  • The patent, which extends until 2012, also covers the use of Talpha1 in combination with interferon-alpha for the treatment of HCV infection.
  • SciClone was previously granted a Japanese patent for the use of Talpha1 in the treatment of HBV infection.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Thymosin / analogs & derivatives. Thymosin / therapeutic use
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Therapy, Combination. Humans. Injections, Subcutaneous. Neoplasms / drug therapy. Structure-Activity Relationship. Virus Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12090542.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / thymalfasin; 61512-21-8 / Thymosin
  • [Number-of-references] 80
  •  go-up   go-down


12. Vihinen P, Vuoristo MS, Hernberg M, Pyrhönen S: [Are immunological treatments beneficial for malignant melanoma of the skin?]. Duodecim; 2010;126(14):1701-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Are immunological treatments beneficial for malignant melanoma of the skin?].
  • Treatment results of metastatic malignant melanoma of the skin have failed to exhibit significant improvement for 30 years.
  • Owing to the poor efficiency of cytotoxic therapies, attention has focused on the patient's own immune system and its strengthening or "teaching" to counteract the melanoma tissue.
  • The most significant forms of immunotherapy currently include the interferons, interleukin-2 and antibody therapy directed against a specific T-lymphocyte associated antigen (CTLA-4).
  • So far, therapeutic vaccines for melanoma have not ended up into routine clinical use.
  • [MeSH-major] Immunotherapy / methods. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antigens, CD. CTLA-4 Antigen. Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Humans. Interferons / immunology. Interferons / therapeutic use. Interleukin-2 / immunology. Interleukin-2 / therapeutic use. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804089.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Cancer Vaccines; 0 / Interleukin-2; 9008-11-1 / Interferons
  • [Number-of-references] 41
  •  go-up   go-down


13. Gehl J, Geertsen PF: Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res; 2000 Dec;10(6):585-9
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy.
  • Electric pulses can cause transient permeabilization of cell membranes (electroporation) and this can be utilized to increase the uptake of chemotherapy (electrochemotherapy).
  • Preclinical studies have shown that in vivo electroporation causes transient shut down of blood flow both in normal and, in particular, malignant tissues.
  • We report the successful palliation of a malignant melanoma patient with bleeding skin metastases using electrochemotherapy.
  • In an on-going study of combined electrochemotherapy and low dose interleukin-2, one patient with bleeding skin metastases was included.
  • Nine skin metastases, of which seven were ulcerated, were treated.
  • The treated metastases developed crusts and the lesions healed in a matter of weeks.
  • Treatments were given under local anaesthesia, lasted a few minutes, and patient discomfort was brief and modest.
  • In conclusion, we propose that electrochemotherapy should be considered for the palliation of haemorrhaging metastases as it is an efficient, tolerable, brief, outpatient, once-only treatment.
  • [MeSH-major] Drug Therapy / methods. Electroporation / methods. Hemorrhage / therapy. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Combined Modality Therapy. Humans. Interleukin-2 / pharmacology. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11198481.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Interleukin-2; 11056-06-7 / Bleomycin
  •  go-up   go-down


14. Neubauer AS, Hoops JP: [Bilateral retinal microangiopathy in interferon therapy of malignant melanoma of the skin]. Klin Monbl Augenheilkd; 2000 Nov;217(5):308-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral retinal microangiopathy in interferon therapy of malignant melanoma of the skin].
  • [Transliterated title] Beidseitige retinale Mikroangiopathie unter Interferon-Therapie bei malignem Melanom der Haut.
  • BACKGROUND: Interferon associated retinopathy has been described mainly by Japanese working groups as a complication of systemic interferon therapy for various diseases.
  • In Europe, only few reports exist, especially regarding interferon therapy for dermal malignant melanoma.
  • PATIENT: We report a 58-year-old female patient with symptomatic, bilateral microangiopathy caused by interferon for metastatic dermal malignant melanoma.
  • The retinal changes were reversible when stopping interferon therapy.
  • CONCLUSION: Interferon-associated microangiopathy occurs as a complication of interferon therapy independently of the treated systemic disease.
  • A regular ophthalmologic monitoring of all patients receiving interferon therapy is recommended.
  • [MeSH-major] Interferon-alpha / adverse effects. Melanoma / drug therapy. Retinal Diseases / chemically induced. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11146832.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


15. Tarhini AA, Christensen S, Frankel P, Margolin K, Ruel C, Shipe-Spotloe J, DeMark M, Kirkwood JM: Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol; 2009 May 20;27(15_suppl):9028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin.
  • METHODS: Phase II study of aflibercept in patients with inoperable stage III or IV melanoma who had received no prior chemotherapy or hormonal therapy.
  • A 2-stage design was adopted focusing upon response rate (RECIST) and 4-month PFS rate.
  • First stage accrual of 21 patients was specified, while final accrual of 41 is planned, with adequate response/4 month PFSR.
  • All had AJCC stage IV melanoma (3M1a, 3M1b, 21M1c).
  • Nine patients had primary ocular melanoma, 16 cutaneous and 2 unknown primary site.
  • Grade 3/4 toxicities included cerebral ischemia (1 patient; 4%), confusion (1; 4%), thrombocytopenia (1; 4%), hypertension (7; 26%), hypotension (1; 4%), left ventricular diastolic dysfunction (1; 4%), fatigue (1; 4%), proteinuria (4; 15%), extraocular muscle paresis (1; 4%), renal failure (1; 4%), back pain (1; 4%), headache (1; 4%).
  • Interim analysis was conducted after the first 21 patients (stage 1).
  • Eight (1 M1a, 1M1b, 6M1c; 4 ocular, 3 cutaneous, 1 unknown primary) of the first 21 patients had at least 4 months of PFS (10 out of 27; 2 additional patients with cutaneous melanoma had SD: 1M1a and 1M1c).
  • One patient (23<sup>rd</sup>; cutaneous, M1c) had a confirmed complete remission.
  • Four patients were taken off study prior to response evaluation for toxicity (3) or treatment refusal (1).
  • One patient is currently disease free who was not evaluable for response (previous surgery and radiofrequency ablation of measurable disease site).
  • CONCLUSIONS: Aflibercept can be administered with acceptable toxicity, and exhibits promising antitumor efficacy against advanced melanoma.
  • This study continues second stage accrual with anticipated closure before June 2009.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kumar L, Menon H, Sharma A, Wadhwa J, Kumar R, Kochupillai V: Acute myeloid leukemia (AML): A study of 516 patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6711

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6711 Background: To review the clinical presentation and treatment outcome.
  • Physical findings were - anemia (96%), icterus (2.4%), skin petechie (24%), gum hypertrophy (24%), lymphnode enlargement (33.7%), splenomegaly (24%), hepatomegaly (42%) and chloroma (2.4%).
  • INVESTIGATIONS: Blood - mean Hb - 6.8 G%, Mean WBC- 47300/cmm, WBC counts were low in 15.8%, normal (16.4%) or high in 67.8%.
  • 266 (51.6%) patients received induction chemotherapy (CT) using 3:7 (80.5%) or 2:5 (7%) or 3:7 + ATRA (3%), low dose Ara-C (6.7%) or others.
  • Comparison between two time periods (1991-1995) and 1996-2000) revealed improvement in both OS (8.8% vs 17%) and LFS (15% vs 25%,p<.05).
  • CONCLUSIONS: Our patients were young and had higher leukemia burden (WBC count >30,000/cmm in >50%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hegde UP, Chakraborty N, Chhabra A, Ray S: Metastatic melanoma in the elderly: Case series of clinical outcome and immune characteristics. J Clin Oncol; 2009 May 20;27(15_suppl):e20018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma in the elderly: Case series of clinical outcome and immune characteristics.
  • : e20018 Background: Cutaneous melanoma incidence is rapidly rising in the elderly population.
  • Imbalances of the immune system are described due to aging associated changes between CD4+, CD8+, T helper (Th) 1, Th 2 and T regulatory and T effector lymphocytes (lym).
  • We describe clinical outcome in 10 elderly patients (pts) with cutaneous metastatic melanoma (CMM) and results of the immune studies done in a subgroup.
  • METHODS: Between October 2002 and October 2008, 10 elderly pts with treatment naïve CMM, 6 males and 4 female, median ages 76, range 57-84 years were treated at the University of Connecticut Health Center.
  • Metastatic sites included soft tissue in 2 patients (pts), lung and/or liver with lymph node (LN) involvement (6 pts) and distant LN metastasis (2pts).
  • Eight pts opted for treatment and received single or combination chemotherapy (5pts), high dose Interleukin 2 (2 pts), complete tumor resection followed by tumor derived heat shock protein vaccine (1 pt on clinical trial) and bio chemotherapy (1pt).
  • One patient declined treatment (included in follow up).
  • In vitro immune characteristics were studied in HLA-A2 positive subgroup (5pts) and included cytotoxic T lym (CTL) generation against self and non self peptides (Mart-1 27-35 and influenza MP derived peptide flu 58-66), proliferative activity of CD4+ lym in response to anti CD3 antibody under Th1 and Th2 conditions and regulatory T lym activity of CD4+CD25+ lym against CTL.
  • RESULTS: All patients tolerated treatments well resulting in 1 complete response, 4 partial responses, and 4 stable diseases.
  • The CTL responses to self and non self antigens were preserved while regulatory T lym showed weak activity against CTL.
  • CONCLUSIONS: Some elderly patients with metastatic melanoma demonstrate improved outcomes and favorable immune characteristics.
  • Further studies are needed to understand the impact of aging immune system on cutaneous melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962552.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Re A, Cattaneo C, Michieli M, Casari S, Spina M, Ferremi P, Mazzuccato M, Carosi G, Tirelli U, Rossi G: High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma.
  • : 6506 Background: The introduction of highly active antiretroviral therapy (HAART), has allowed the evaluation of aggressive therapeutic approaches in HIV-associated lymphoma (HIV-Ly).
  • METHODS: We report the results of a multiinstitutional program of high dose therapy (HDT) and autologous peripheral blood stem cell (PBSC) transplantation in HAART responsive pts with HIV-Ly refractory or relapsed after standard dose chemotherapy (CT).
  • RESULTS: Twentyfive pts entered the study: 10 HD (five 1<sup>st</sup> relapse, two 2<sup>nd</sup> relapse, three refractory) and 15 NHL (eight 1<sup>st</sup> relapse, one 2<sup>nd</sup> relapse, two partial remission (PR), four refractory).
  • Median age was 38 (28-56) and CD4 count 207/cmm (17-506).
  • Two had early disease progression; one is on treatment and 14 received the BEAM regimen and PBSC transplantation with prompt engraftment in all (neutrophils and plt engraftment: 10 (8-10) and 12 days (8-18)).
  • Treatment-related toxicities (WHO grade 3-4): 3 oral mucositis (3) and 2 hepatic toxicity (3).
  • CD4 count decreased after treatment, but a trend toward recovery is seen few mo after transplant.
  • 12/13 evaluable (1 is too early) pts (92%) achieved CR and 1 PR.
  • CONCLUSIONS: Our data confirm on a multiinstitutional basis that HDT and PBSC transplantation is feasible and active as salvage therapy in HIV-Ly in unselected HAART responding patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Patel S, Bedikian A, Kim K, Papadopoulos N, Hwu P, Vardeleon A, Prieto V, Bar Eli M, Bronstein Y, Bassett R Jr: A phase II study of gefitinib in patients with metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gefitinib in patients with metastatic melanoma.
  • : 9057 Background: Gefitinib is an inhibitor of epidermal growth factor receptor (EGFR), which is frequently expressed on both choroidal and non-choroidal melanoma cells.
  • We evaluated the clinical efficacy of gefitinib in patients (pts) with metastatic melanoma.
  • METHODS: Pts with stage IV or unresectable or recurrent stage III melanoma and Zubrod performance status of 0 to 2 were eligible.
  • For non-choroidal melanoma, pts must have received systemic cytotoxic therapy, but no more than 2 regimens; for choroidal melanoma, pts could be either chemo-naïve or have received up to 2 systemic cytotoxic therapies.
  • Ten patients with cutaneous disease were also consented for paired biopsies and blood collection for correlative studies at baseline and after 3 weeks of treatment.
  • RESULTS: Fifty-two pts (46 non-choroidal; 6 choroidal primay) were treated and evaluated for toxicity, and 50 pts were evaluable for response.
  • The median number of prior systemic treatments was 1.
  • Forty-one pts (79%) had stage M1c disease.
  • There were no drug-related grade 4 or 5 adverse events (AEs), and fatigue was the only grade 3 AEs in >5% of the patients.
  • There were 2 (4%) partial responses, including a pt with metastatic choroidal melanoma, and 13 pts (26%) had disease stabilization.
  • Median time to progression was 6 weeks, and median overall survival was 4.6 months.
  • Among 7 pts with sufficient tissue on paired biopsies, there were no notable trends in the changes of the expression of pERK1/2, pAKT, or pPAK1 with treatment.
  • Additionally, no trends were identified in serum VEGF or IL-8 levels after treatment.
  • CONCLUSIONS: Gefitinib was well tolerated, but had minimal clinical efficacy as a single-agent therapy for metastatic melanoma of cutaneous origin.
  • There were no consistent changes in the expressions of downstream kinase proteins with gefitinib treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962131.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Goyal A, Evans WD, Mansel RE: Isolated hyperthermic chemotherapy perfusion for limb melanoma is a safe procedure. J Clin Oncol; 2004 Jul 15;22(14_suppl):7538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated hyperthermic chemotherapy perfusion for limb melanoma is a safe procedure.
  • : 7538 Background: Isolated limb perfusion(ILP) delivers high dose of chemotherapeutic agent to an extremity with multiple in-transit lesions from cutaneous melanoma.
  • METHODS: 53 perfusions were performed using melphalan, 1.5-2mg/kg (13 prophylactic, 40 therapeutic) and 3 using melphalan in combination with other chemotherapeutic agents (all therapeutic).
  • 75% of the patients had MD Anderson stage III disease.
  • Overall 5-year survival rate was 49% for therapeutic perfusion and 100% for prophylactic perfusion.
  • CONCLUSION: Therapeutic ILP is a suitable treatment for in-transit metastases not amenable to surgery and confined to a limb, since amputation provides no advantage in terms of survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014919.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z: Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res; 2000 Aug;10(4):381-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases.
  • The application of electric pulses to skin tumour nodules enhances the antitumour effectiveness of cisplatin.
  • This treatment approach, known as electrochemotherapy, was employed in the treatment of skin metastases and lymph node metastases in malignant melanoma patients.
  • The study included nine malignant melanoma patients with skin metastases and metastases in lymph nodes not amenable to surgery, undergoing cisplatin-based chemoimmunotherapy.
  • Application of electric pulses to the 27 skin tumour nodules potentiated locally the antitumour effectiveness of cisplatin.
  • Four weeks after the treatment, 48% of the tumour nodules had an objective response (OR), compared with 22% of the 18 tumour nodules treated with cisplatin-based chemoimmunotherapy alone.
  • Furthermore, the median time to progression was longer in the electrochemotherapy-treated nodules (21 weeks) than in the chemoimmunotherapy-treated nodules (4 weeks).
  • This study shows that application of electric pulses to malignant melanoma tumour nodules can potentiate the antitumour effectiveness of cisplatin in patients undergoing systemic cisplatin-based chemoimmunotherapy.
  • Therefore, electrochemotherapy may be used as an adjunct to systemic ongoing cisplatin treatment, predominantly in patients in whom antitumour effectiveness needs to be potentiated locally.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Electric Stimulation Therapy / methods. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Synergism. Electroporation. Female. Follow-Up Studies. Humans. Lymph Nodes / drug effects. Lymphatic Metastasis. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985673.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Palazzi MA, Ober MD, Abreu HF, Cardinalli IA, Isaac CR, Odashiro AN, Burnier Jr MN: Congenital uveal malignant melanoma: a case report. Can J Ophthalmol; 2005 Oct;40(5):611-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital uveal malignant melanoma: a case report.
  • CASE REPORT: We present a case of congenital choroidal mass in a male infant with multiple cutaneous pigmented lesions.
  • Enucleation performed in the first weeks of life confirmed the diagnosis of diffuse uveal malignant melanoma with extraocular extension.
  • The patient was also treated with 5 cycles of chemotherapy.
  • He subsequently developed cutaneous and ocular pigmented lesions, including 2 choroidal nevi located within the posterior pole and a benign conjunctival lesion in the opposite eye, in addition to malignant melanoma of the skin.
  • We believe this represents the fourth case ever reported in the literature and the longest follow-up of a congenital malignant melanoma originating within the eye.

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391626.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


23. Schultz ES, Schuler G: [Malignant melanoma. Diagnosis and therapy]. HNO; 2005 Nov;53(11):928-39
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma. Diagnosis and therapy].
  • [Transliterated title] Malignes Melanom. Diagnostik und Therapie.
  • In Germany, 6100 women and 5300 men contract a malignant melanoma of the skin every year.
  • Therefore, early diagnosis is crucial, particularly as the skin is, by nature, a readily accessible organ.
  • A light skin type, presence of numerous naevi, genetic predisposition (familial history) and increased UV exposure are considered as risk factors.
  • A multidisciplinary approach consisting of surgery, radiotherapy, chemotherapy and immunotherapy has proved beneficial in advanced stages of metastasis.
  • [MeSH-major] Melanoma / diagnosis. Otorhinolaryngologic Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Prognosis. Skin / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1982;10(3):251-8 [7045615.001]
  • [Cites] Hautarzt. 1998 Oct;48 Suppl 1:S30-8 [9866046.001]
  • [Cites] Cancer. 1996 May 1;77(9):1809-14 [8646678.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):579-86 [11568750.001]
  • [Cites] Melanoma Res. 1996 Feb;6(1):55-62 [8640071.001]
  • [Cites] Strahlenther Onkol. 1999 Sep;175(9):450-7 [10518979.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1118-25 [15020614.001]
  • [Cites] Melanoma Res. 1999 Oct;9(5):491-502 [10596916.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1633-40 [8983267.001]
  • [Cites] Melanoma Res. 2002 Apr;12 (2):175-8 [11930115.001]
  • [Cites] Immunol Rev. 2002 Oct;188:51-64 [12445281.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):34-42 [7804974.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):356S-362S [8440924.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):540-3 [7776772.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):280-90 [11586069.001]
  • [Cites] J Am Acad Dermatol. 1994 Apr;30(4):551-9 [8157780.001]
  • [Cites] Ann Surg Oncol. 1998 Jun;5(4):322-8 [9641453.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1237-42 [8343260.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):628-38 [12548604.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12 ):2444-58 [10856105.001]
  • [Cites] J Am Acad Dermatol. 2002 May;46(5):690-4 [12004308.001]
  • [Cites] J Am Coll Surg. 1995 Jan;180(1):65-71 [8000657.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2045-52 [11956264.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1600-7 [11896110.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):11-20 [9420067.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1183-7 [9379142.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1425-9 [9552047.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1493-8 [10584702.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):736-40 [2016616.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):569-72 [10944593.001]
  • [Cites] Curr Top Microbiol Immunol. 2003;276:163-97 [12797448.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):438-41 [2009058.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S177-86 [10938658.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1373-86 [9338460.001]
  • [Cites] Lancet. 1998 Mar 14;351(9105):793-6 [9519951.001]
  • [Cites] Dtsch Med Wochenschr. 1997 Feb 14;122(7):177-81 [9072487.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1060-6 [10091789.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):159-65 [11902502.001]
  • [Cites] Lancet. 1998 Jun 27;351(9120):1905-10 [9654256.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):97-103 [12569292.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2058-66 [11956266.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10 (5):1670-7 [15014018.001]
  • [Cites] Radiother Oncol. 1992 Mar;23(3):185-91 [1574597.001]
  • [Cites] Hautarzt. 1990 Feb;41(2):56-65 [2180855.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):859-64 [2460420.001]
  • [Cites] Lancet. 1989 Aug 26;2(8661):487-90 [2570195.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):390-402 [14746858.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2556-62 [7020916.001]
  • [Cites] Cancer Treat Rev. 2004 Oct;30(6):515-20 [15325032.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2119-30 [8156517.001]
  • [Cites] J Am Acad Dermatol. 1987 Sep;17(3):459-68 [3655025.001]
  • [Cites] N Engl J Med. 1982 Oct 7;307(15):913-6 [7050717.001]
  • [Cites] Eur J Cancer. 1978 Apr;14(4):327-30 [648555.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):2074-87 [7427913.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):179-84 [11870502.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):679-93 [12734496.001]
  • [Cites] J Clin Oncol. 1984 Mar;2(3):164-8 [6199481.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1036-44 [8164027.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Br J Cancer. 1997;76(2):256-9 [9231928.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4181-90 [12377961.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1079-84 [7037155.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1146-9 [11379605.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 21;85(8):622-32 [8468720.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1151-6 [2045856.001]
  • [Cites] Melanoma Res. 1999 Dec;9(6):611-3 [10661774.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1692-8 [15073858.001]
  • [Cites] J Clin Oncol. 1996 Jan;14 (1):7-17 [8558223.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2370-80 [11331315.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1061-5 [3409184.001]
  • [Cites] Eur J Dermatol. 2001 May-Jun;11(3):270-6; quiz 277 [11358742.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1368-74 [9849419.001]
  • [Cites] Ann Intern Med. 1985 Apr;102(4):458-65 [3977193.001]
  • [Cites] Ann Surg. 1993 Sep;218(3):262-7; discussion 267-9 [8373269.001]
  • [Cites] Cancer Surv. 1994;19-20:219-40 [7534627.001]
  • (PMID = 16167149.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 82
  •  go-up   go-down


24. Padsis J, Turley R, Tyler D: Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother; 2010 Jan;11(1):79-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy of regional melanoma therapy.
  • IMPORTANCE OF THE FIELD: In-transit melanoma metastases develop within regional dermal and subdermal lymphatics before reaching the regional lymph nodes.
  • Isolated limb infusion (ILI) or perfusion (ILP) are effective treatments for unresectable, in-transit melanoma, with response rates reaching 95%.
  • Although ILI and ILP are more effective than systemic therapy, most patients will recur, thus highlighting the need for newer strategies to improve durable response rates.
  • AREAS COVERED IN THIS REVIEW: We review historical and current literature from 1958 to 2009 regarding regional therapy for melanoma, with focus on the ILI and ILP techniques, pharmacokinetics and resistance mechanisms of melphalan.
  • Alternative therapies, adjunct strategies and new targeted therapies aimed at improving response rates and long-term remission are also discussed.
  • WHAT THE READER WILL GAIN: The reader will gain a comprehensive review on regional pharmacotherapy for melanoma, including alternative therapies, adjunct strategies and new targeted therapies.
  • TAKE HOME MESSAGE: Regional chemotherapy is a viable, evolving treatment for patients with in-transit melanoma and a springboard for ongoing research aimed at improving therapies for malignant melanoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Extremities / pathology. Lymphatic Metastasis / pathology. Melanoma / pathology. Melphalan / therapeutic use. Neoplasm Recurrence, Local
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Humans. Hyperthermia, Induced / methods. Infusions, Intra-Arterial. Skin Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001431.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


25. Winnepenninckx V, Van den Oord JJ: Gene expression profiling of primary cutaneous melanoma. Verh K Acad Geneeskd Belg; 2007;69(1):23-45
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of primary cutaneous melanoma.
  • Cutaneous Malignant Melanoma (CMM) is the most malignant skin tumour in humans, the incidence of which is rising rapidly in most fair-skinned populations, without apparent decline in mortality.
  • CMM arises from melanocytes in the epidermis, and proceeds through discrete steps of tumor-progression that consist histologically of the radial growth phase (RGP), vertical growth phase (VGP) and metastatic phase.
  • The prognosis of patients with VGP melanoma depends on several clinical and histological parameters; the latter include thickness, mitotic activity, presence or absence of ulceration and regression, and pattern of lymphocytic host response.
  • To obtain insight in the molecular mechanisms of tumor progression in CMM, and in search of new prognostic markers, we performed global gene-expression profiling using 44K oligonucleotide micro-arrays on a unique retrospective series of 83 frozen primary MM with VGP, 9 metastases and 23 benign nevi.
  • Unsupervised analysis allowed us o identify clusters of melanoma patients with different outcome based on their gene expression profile only.
  • The large majority of the 254 enes was correlated with thickness, thereby stressing the importance of thickness in he prognosis of CMM.
  • This signature was validated on a separate series of melanoma patients, and proved to have a predictive accuracy comparable to what can be obtained by tumour thickness and ulceration.
  • On an immunohistochemical level, we identified 8 new markers that may help in the prognostication of melanoma patients; three of these markers, i.e. the mini-chromosome maintenance (mcm) proteins mcm3, 4 and 6, hat are involved in DNA-replication, had independent prognostic value.
  • Additionally, upervised analysis showed similarities in gene expression profile between primary CMM and their metastases.
  • In conclusion, our data provide new information regarding the molecules that are operative in the progression of CMM.
  • CMM is notorious for its resistance to chemotherapy, and disseminated CMM is a uniformly fatal disease.
  • As several of the progression-related genes, encode molecules that have been the target of established or xperimental cancer therapies, our results may hopefully contribute to the treatment of end-stage CMM-patients.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Melanoma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427873.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 54
  •  go-up   go-down


26. Lens MB, Eisen TG: Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother; 2003 Dec;4(12):2205-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy in the treatment of malignant melanoma.
  • Different postsurgical therapies are used for the treatment of metastatic melanoma.
  • This article reviews the use of chemotherapeutic agents in the treatment of patients with metastatic malignant melanoma.
  • A variety of single chemotherapy agents have been evaluated, although the most widely used chemotherapeutic in the treatment of metastatic melanoma is dacarbazine.
  • In order to improve the rate and duration of responses, combination chemotherapy was developed.
  • The most common combined chemotherapy regimens used as standard for the treatment of metastatic melanoma are Dartmouth regimen, CVD (cisplatin + vinblastine + dacarbazine) and BOLD (bleomycin + vincristine + lomustine + dacarbazine).
  • The use of classical systemic chemotherapy still has a role in the treatment of patients with metastatic melanoma.
  • Immunotherapy and biochemotherapy have no additional advantage over chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / therapeutic use. Carmustine / therapeutic use. Cisplatin / therapeutic use. Clinical Trials as Topic. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Humans. Lomustine / therapeutic use. Neoplasm Metastasis. Tamoxifen / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14640919.001).
  • [ISSN] 1465-6566
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine; BOLD protocol; CVD protocol; DBPT regimen
  • [Number-of-references] 50
  •  go-up   go-down


27. Kretschmer L, Helmbold P, Emmert S, Marsch WC: [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma]. Hautarzt; 2002 Aug;53(8):536-41
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
  • [Transliterated title] Langzeitergebnisse der adjuvanten Chemotherapie nach therapeutischer Lymphknotendissektion beim malignen Melanom der Haut.
  • BACKGROUND AND OBJECTIVE: 224 patients with malignant melanoma and palpable axillary or inguinal lymphadenopathy underwent therapeutic lymph node dissection at the Martin-Luther-University in Halle, Germany. between 1983 and 1994.
  • 120 received adjuvant chemotherapy; we evaluated the effects of various regimens in this group.
  • PATIENTS/METHODS: Surgical treatment alone was performed in 104 patients.
  • The 5-year survival rates were 31.0+/-5% after surgery alone, 26.4+/-4% after adjuvant polychemotherapy and 27.0+/-9% after DTIC based chemotherapy.
  • In a multifactorial analysis, the number of metastatic lymph nodes was the single significant predictor of survival after therapeutic lymph node dissection, whereas Breslow thickness, ulceration, site of the primary melanoma, age, sex and adjuvant therapy were not significant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / administration & dosage. Interferon-alpha / administration & dosage. Lymph Node Excision. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12221468.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Evaluation Studies; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interferon-alpha; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


28. Melichar B, Dvorák J, Jandík P, Tousková M, Solichová D, Megancová J, Voboril Z: Intraarterial chemotherapy of malignant melanoma metastatic to the liver. Hepatogastroenterology; 2001 Nov-Dec;48(42):1711-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial chemotherapy of malignant melanoma metastatic to the liver.
  • BACKGROUND/AIMS: The prognosis of malignant melanoma metastatic to the liver is poor.
  • The aim of the present report was to analyze retrospectively the effectiveness of regional chemotherapy and biologic therapy in patients with hepatic metastases of malignant melanoma.
  • METHODOLOGY: Seven patients with hepatic metastases of malignant melanoma were treated by intraarterial administration of the combination of cisplatin, vinblastine and dacarbazine, or melphalan, with or without interleukin-2, interferon-alpha and interferon-gamma.
  • CONCLUSIONS: Regional intraarterial administration of chemotherapy with or without cytokines may be effective for controlling hepatic metastases of malignant melanoma in patients with disease limited to the liver, but little benefit is evident in patients who present with concurrent extrahepatic disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Infusions, Intra-Arterial. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melanoma / drug therapy. Melanoma / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Palatal Neoplasms / pathology. Skin Neoplasms / pathology. Uvula

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11813606.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


29. Demirci H, McCormick SA, Finger PT: Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol; 2000 Jul;118(7):885-91
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.
  • OBJECTIVES: To clinically evaluate topical mitomycin chemotherapy in patients with diffuse, multifocal, or recurrent primary acquired melanosis with atypia and/or conjunctival malignant melanoma and to histopathologically study ocular tissue samples obtained before and after treatment.
  • METHODS: Chemotherapy with topical mitomycin, 0.04% 4 times daily, was administered for 28 days as the primary and only treatment in 7 patients (after biopsy) and for 7 days as adjuvant therapy to excision and cryotherapy in 5 patients.
  • Five patients developed subconjunctival recurrences, for which 2 underwent orbital exenteration and 3 were treated conservatively.
  • Histopathologic specimens of conjunctival, adnexal, and ocular tissues obtained before and after chemotherapy were evaluated.
  • RESULTS: Regression of tumor was observed in 11 patients with primary or adjuvant topical mitomycin chemotherapy.
  • One patient with nodular melanoma was resistant to mitomycin chemotherapy.
  • Two patients with primary treatment and 2 with adjuvant treatment developed subconjunctival recurrence.
  • In patients with recurrent malignant melanoma, the deeper layers of the lamina propria were involved, with sparing of the epithelium and superficial lamina propria.
  • Transient keratoconjunctivitis was observed in all patients during treatment.
  • CONCLUSIONS: Topical mitomycin chemotherapy was found to induce regression of conjunctival melanoma and primary acquired melanosis with atypia.
  • When mitomycin chemotherapy was used as an adjuvant to excision and cryotherapy, 2 (40%) of 5 patients experienced tumor recurrence at a mean of 4.3 years' follow-up.
  • Our histopathologic findings demonstrated a long-term mitomycin chemotherapy-related effect on the conjunctiva.
  • The pattern of effect and location of recurrent disease suggest that this regimen of topical mitomycin chemotherapy was most effective for superficial tumors.
  • Although subconjunctival or orbital recurrences were noted, topical mitomycin chemotherapy warrants further investigation as an alternative treatment for primary acquired melanosis with atypia and conjunctival malignant melanoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Melanoma / drug therapy. Melanosis / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Atrophy / chemically induced. Chemotherapy, Adjuvant. Conjunctiva / drug effects. Conjunctiva / pathology. Cryotherapy. Drug Evaluation. Female. Humans. Keratoconjunctivitis / chemically induced. Male. Middle Aged. Neoplasm Recurrence, Local. Ophthalmic Solutions / administration & dosage. Ophthalmic Solutions / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10900099.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


30. Tas F, Camlica H, Kurul S, Aydiner A, Topuz E: Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma. Clin Oncol (R Coll Radiol); 2003 May;15(3):132-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
  • AIM: The aim of the current trial was to assess the efficacy and toxicity of 3-weekly intravenous docetaxel and irinotecan in the treatment of patients with metastatic malignant melanoma.
  • MATERIALS AND METHODS: Sixteen patients with no history of previous cytotoxic agents or immunological treatment for advanced disease were treated with docetaxel 50 mg/m2 and irinotecan 150 mg/m2 intravenously over 60 min every 21 days.
  • Prior immunotherapy with interferon and chemotherapy for adjuvant therapies were accepted provided there was a minimum 4-week treatment-free interval.
  • RESULTS: None of the patients had chemotherapy-induced tumour response.
  • The median survival time was 136 days (95% CI: 30.2-241.8), and the 3-month survival rate was 62.5%.
  • Patients with stable disease (n = 8) had a longer survival than non-responders (P = 0.023, Breslow test).
  • CONCLUSION: A 3-weekly intravenous docetaxel and irinotecan combination appears to be inactive in the treatment of patients with malignant melanoma and has not been recommended.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Melanoma / drug therapy. Paclitaxel / analogs & derivatives. Skin Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801051.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


31. Jin S, Zhang Q, Kang X, Wang J, Sun W: Malignant melanoma therapy by chemotherapy and autoimmunity induced by cytokine. Cancer Biother Radiopharm; 2009 Apr;24(2):237-41
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma therapy by chemotherapy and autoimmunity induced by cytokine.
  • PURPOSE: The aim of this study was to evaluate the effect of combining dacarbazine (DTIC) and granulocyte/macrophage colony-stimulating factor (GM-CSF) with interleukin-2 (IL-2) in patients with advanced malignant melanoma.
  • METHODS: Twenty-seven (27) patients with advanced malignant melanoma received dacarbazine (500 mg/m(2)/days 1-2, intravenously), GM-CSF (175 ug/m(2)/days 3-6, subcutaneously), and interleukin-2 (400 MIU/m(2)/days 7-10, subcutaneously).
  • Each treatment cycle required 21 days to completion.
  • RESULTS: Time to progression was 7-11 months.
  • The total effective rate was 44.4%, and the combination of chemotherapy, GM-CSF, and IL-2 had low toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Adult. Autoimmunity / drug effects. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Drug Interactions. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects. Humans. Immunotherapy. Interleukin-2 / administration & dosage. Interleukin-2 / adverse effects. Male. Middle Aged. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409046.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


32. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D: Metastatic melanoma: chemotherapy. Semin Oncol; 2002 Oct;29(5):427-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma: chemotherapy.
  • The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of 47,700 new cases diagnosed in 2000 in the United States.
  • In the early phase of its natural history, melanoma is cured in most cases by surgery, but once the metastatic phase develops, it is almost always fatal.
  • The treatment of metastatic melanoma remains unsatisfactory.
  • Systemic therapy has not been successful up to now, with very low response rates to single-agent chemotherapy.
  • New chemotherapeutic and biologic agents are now available and promising combined approaches targeting the tumor by several different mechanisms are desirable and will probably represent the future modality of treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Melanoma / secondary. Taxoids
  • [MeSH-minor] Bridged Compounds / therapeutic use. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Clinical Trials as Topic. Cytokines / therapeutic use. Dacarbazine / therapeutic use. Genetic Therapy / methods. Humans. Immunotherapy / methods. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use. Paclitaxel / therapeutic use. Tamoxifen / therapeutic use. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. Fotemustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12407508.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bridged Compounds; 0 / Cytokines; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 1605-68-1 / taxane; 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; BG3F62OND5 / Carboplatin; GQ7JL9P5I2 / fotemustine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 142
  •  go-up   go-down


33. Tezuka K, Inaba Y, Hayashi K, Miura T, Moriya T, Takiguchi M, Isobe H, Watabe S, Yanagawa N: [A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1709-12
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy].
  • We report a case on hemodialysis with liver metastases from anorectal malignant melanoma treated by dacarbazine (DTIC).
  • An elastic soft mass was palpated in the anal canal, and a biopsy specimen was diagnosed as anorectal malignant melanoma histologically.
  • Two and a half years after surgery, computed tomography showed multiple liver metastases.
  • We chose chemotherapy consisting of DTIC 100 mg for five consecutive days every 4 weeks in addition to hemodialysis (3 times a week).
  • After three cycles of chemotherapy, liver metastases were stable, but new lung metastases were found.
  • After 12 cycles of chemotherapy, liver metastases became stable, but lung metastases were progressive.
  • Subsequently, the patient died of respiratory failure 4 years after surgery, 1 year and 7 months after the diagnosis of multiple liver metastases.
  • We conclude that administration of DTIC undergoing hemodialysis for malignant melanoma with renal failure seems to be useful without severe adverse events.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Anus Neoplasms / pathology. Dacarbazine / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melanoma / drug therapy. Renal Dialysis
  • [MeSH-minor] Humans. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940397.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


34. Paciucci PA, Ryder JS, Mandell JP, Morris JC, Holland JF: Interleukin-2 plus chemotherapy for patients with metastatic melanoma. Melanoma Res; 2000 Jun;10(3):291-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-2 plus chemotherapy for patients with metastatic melanoma.
  • We studied the activity of recombinant interleukin-2 (IL2) in combination with multiagent chemotherapy in the treatment of patients with disseminated malignant melanoma.
  • All patients received a chemotherapy regimen consisting of lomustine (CCNU) 75 mg/m2 on day 14, bleomycin 10 units/day by CI for 5 days (days 14-19) and cisplatin 75 mg/m2 on day 19.
  • The median duration of survival was 6.7 months in non-responders and 11.1 months in responders.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interleukin-2 / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Lomustine / administration & dosage. Male. Middle Aged. Recombinant Proteins / administration & dosage. Recombinant Proteins / therapeutic use. Remission Induction. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10890384.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-P30-CA23102
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Matsutani T, Onda M, Miyashita M, Hagiwara N, Akiya Y, Takubo K, Yamashita K, Sasajima K: Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy. Dis Esophagus; 2001;14(3-4):241-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy.
  • We describe herein a case of asymptomatic primary malignant melanoma of the esophagus.
  • Postoperatively, the patient received five cycles of systemic chemotherapy with dacarbazine (DTIC), nimustine hydrochloride (ACNU), and vincristine (VCR) (DAV therapy), but ultimately died of generalized metastatic disease 15 months after surgery.
  • Malignant melanoma of the esophagus has an extremely poor prognosis despite various therapeutic efforts.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11869329.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


36. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R: Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res; 2009 Oct 1;15(19):6158-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.
  • PURPOSE: To test combination treatment schedules of reovirus and cisplatin chemotherapy in human and murine melanoma cell lines and murine models of melanoma and to investigate the possible mechanisms of synergistic antitumor effects.
  • EXPERIMENTAL DESIGN: The effects of reovirus +/- chemotherapy on in vitro cytotoxicity and viral replication were assessed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay and plaque assay.
  • Mode of cell death was assessed by Annexin V/propidium iodide fluorescence-activated cell sorting-based assays; gene expression profiling of single versus combination treatments was completed using the Agilent microarray system.
  • Single agent and combination therapy effects were tested in vivo in two immunocompetent models of murine melanoma.
  • RESULTS: Variable degrees of synergistic cytotoxicity between live reovirus and several chemotherapy agents were observed in B16.F10 mouse melanoma cells, most significantly with cisplatin (combination index of 0.42 +/- 0.03 at ED(50)).
  • Combination therapy led to significantly delayed tumor growth and improved survival in vivo (P < 0.0001 and P = 0.0003, respectively).
  • However, cisplatin treatment suppressed the cytokine and chemokine response to reovirus in vitro and in vivo.
  • CONCLUSION: The combination of reovirus and several chemotherapeutic agents synergistically enhanced cytotoxicity in human and murine melanoma cell lines in vitro and murine tumors in vivo.
  • The data support the current reovirus/chemotherapy combination phase I clinical studies currently ongoing in the clinic.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Melanoma, Experimental / therapy. Oncolytic Virotherapy. Reoviridae / physiology
  • [MeSH-minor] Animals. Apoptosis / physiology. Combined Modality Therapy. Humans. Mice. Mice, Inbred C57BL. NIH 3T3 Cells. Oncolytic Viruses / physiology. Treatment Outcome. Tumor Cells, Cultured. Virus Replication / drug effects

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773377.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Novik AV, Novik BI, Moiseenko VM: [Prognostic significance of DNA ploidy in disseminated malignant skin melanoma and the effectiveness of interleukin-2 (IL-2) treatment]. Vopr Onkol; 2007;53(2):164-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of DNA ploidy in disseminated malignant skin melanoma and the effectiveness of interleukin-2 (IL-2) treatment].
  • Retrospective study of DNA ploidy was performed on cytologic slides derived from 30 patients with malignant melanoma (stage IV) before interleukin-2 (IL-2) treatment.
  • Twelve patients were tested after two courses of treatment.
  • Significant differences in survival versus DNA ploidy (p=0.025) and response to treatment (p=0.016) were found by use of single-factor analysis (Caplan-Meyer).
  • However, multivariate proportional-hazard regression method (Cox) identified high prognostic relevance (p=0.00007) of a combination of 5 factors: DNA ploidy (p=0.008), gender (p=0.015), blood group (p=0.015), sum total of metastasis diameter (p=0.035) and response to treatment (p=0.042).
  • Significant drop in DNA level after treatment was reported in 9 out of 12 patients; no change - 1 and a rise in 2.
  • The post treatment increase involved rapid progression of tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Neoplasm. Interleukin-2 / therapeutic use. Melanoma / drug therapy. Melanoma / genetics. Ploidies. Skin Neoplasms / drug therapy. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663169.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Interleukin-2
  •  go-up   go-down


38. Conill C, Jorcano S, Domingo-Doménech J, Gallego R, Malvehy J, Puig S, Sánchez M, Vilella R, Castel T: Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. Clin Transl Oncol; 2006 Apr;8(4):266-70
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
  • INTRODUCTION: Whole brain irradiation (WBRT) remains a recommended treatment for patients with brain metastases from malignant melanoma in terms of symptom palliation, especially when extracranial systemic disease is present.
  • Temozolomide (TMZ) has shown efficacy in the treatment of metastatic melanoma.
  • The objective was to evaluate the potential benefit in survival of two different schedules of total dose and fractionation (20 Gy/5 fractions vs 30 Gy/10 fractions) and further TMZ based chemotherapy.
  • MATERIALS AND METHOD: We have conducted a retrospective study in a group of twenty-one patients (RTOG Recursive Partitioning Analysis class II) of the use of WBRT with 20 Gy/5 fractions (n = 11) and 30 Gy/10 fractions (n = 10).
  • All patients received further TMZ based chemotherapy administered as a single chemotherapeutic agent or in combination with chemo-immunotherapy.
  • RESULTS: Prognostic variables such as: age, Karnofsky performance status, extracranial metastases and number of brain metastases, were analyzed in both groups of treatment without statistically significant differences.
  • The median survival time (MST) for WBRT 20 Gy group was 4 months (CI 95%: range 2- 6 months) and for WBRT 30 Gy group was 4 months (CI 95%: range 0-7 months) without statistically significant differences (Log rank p = 0.74).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Cranial Irradiation. Dacarbazine / analogs & derivatives. Melanoma / secondary
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cohort Studies. Combined Modality Therapy. Drug Administration Schedule. Drug Evaluation. Female. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Life Tables. Male. Middle Aged. Patient Selection. Proportional Hazards Models. Recombinant Proteins. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Apr 15;94(8):2265-72 [12001126.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):621-2 [11529230.001]
  • [Cites] Melanoma Res. 2004 Feb;14 (1):73-4 [15091198.001]
  • [Cites] Melanoma Res. 2002 Apr;12 (2):175-8 [11930115.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Apr;128(4):214-8 [11935312.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):173-8 [10533730.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1864-6 [2317765.001]
  • [Cites] Med Clin (Barc). 2002 Nov 30;119(19):758-9 [12487980.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):93-7 [11163501.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):243-6 [3334956.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2550-2 [6713349.001]
  • [Cites] Melanoma Res. 2004 Aug;14 (4):289-94 [15305160.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):97-103 [12569292.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):679-83 [6766793.001]
  • [Cites] Cancer. 1954 Jul;7(4):682-9 [13172684.001]
  • [Cites] Med Clin (Barc). 2004 Mar 27;122(11):413-5 [15066248.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] Med Clin (Barc). 2004 Oct 2;123(11):437 [15482724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6 [10863071.001]
  • (PMID = 16648102.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin; YF1K15M17Y / temozolomide
  •  go-up   go-down


39. Kurli M, Finger PT: Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol; 2005 Nov;243(11):1108-14
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.
  • PURPOSE: To report 12-year follow-up experience with topical mitomycin chemotherapy for diffuse and multifocal primary acquired melanosis (PAM) with atypia and conjunctival melanoma.
  • Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma.
  • Primary treatments consisted of mitomycin 0.04% qid for 28 days (two 14-day cycles) and for 7 consecutive days as adjuvant therapy.
  • RESULTS: Sixteen patients were followed for a mean 81 months (range 13-144 months) after treatment.
  • All tumors responded to chemotherapy.
  • Recurrence was noted in eight (three adjuvant and five primary treatment patients).
  • The mean time to recurrence was 36.9 months.
  • Three patients died, one of metastatic conjunctival melanoma.
  • CONCLUSIONS: Conjunctival melanoma and PAM responded to mitomycin 0.04% topical chemotherapy; subepithelial nests appeared resistant to treatment.
  • Treatment-related complications were acceptable.
  • In this series, as primary and adjuvant therapy, topical mitomycin yielded an overall recurrence rate of 50%.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Melanoma / drug therapy. Melanosis / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 2003 Jun;135(6):800-6 [12788119.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):252-9 [8199108.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1998 May;14(3):208-15 [9612814.001]
  • [Cites] Ophthalmology. 1989 Feb;96(2):147-66 [2649838.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):317-21 [2023752.001]
  • [Cites] Ophthalmology. 1982 May;89(5):502-15 [7099571.001]
  • [Cites] Br J Ophthalmol. 1990 Oct;74(10):615-9 [2285686.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Cornea. 2002 Oct;21(7):715-7 [12352093.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):72-8; discussion 79 [9917784.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2567-74 [6790156.001]
  • [Cites] Cornea. 2003 Mar;22(2):114-7 [12605043.001]
  • [Cites] Cornea. 2003 Oct;22(7):627-39 [14508259.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1617-22 [10845577.001]
  • [Cites] Trans Am Ophthalmol Soc. 1980;78:467-502 [7257067.001]
  • [Cites] Surv Ophthalmol. 2001 Mar-Apr;45(5):416-44 [11274695.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1012-6 [12750105.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):244-5 [11815356.001]
  • [Cites] Ophthalmology. 1995 Oct;102(10):1569-71 [9097808.001]
  • [Cites] Am J Ophthalmol. 1992 Oct 15;114(4):503-4 [1415465.001]
  • [Cites] Cornea. 2002 Nov;21(8):838-9 [12410049.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Ophthalmology. 1988 Aug;95(8):1058-70 [3231444.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1996 Sep;234(9):569-72 [8880155.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Br J Ophthalmol. 1994 Jul;78(7):520-8 [7522545.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1756-60; discussion 1761 [10485547.001]
  • [Cites] Ophthalmology. 1988 Jun;95(6):813-21 [3211484.001]
  • [Cites] Arch Ophthalmol. 1980 Aug;98(8):1385-9 [7417073.001]
  • [Cites] Br J Ophthalmol. 1993 Oct;77(10):624-30 [8218029.001]
  • (PMID = 15940485.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


40. Vorobiof DA, Rapoport BL, Mahomed R, Karime M: Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res; 2003 Apr;13(2):201-3
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment.
  • Fourteen patients with metastatic malignant melanoma that had failed to respond to standard dacarbazine-based chemotherapy treatment were entered into a phase II study of pegylated liposomal doxorubicin (Caelyx) given as a single intravenous injection at a dose of 50 mg/m(2) at 28 day intervals.
  • Treatment was well tolerated.
  • We conclude that pegylated liposomal doxorubicin does not demonstrate sufficient activity in metastatic melanoma to warrant further investigation in this setting.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / therapeutic use. Liposomes / metabolism. Melanoma / drug therapy. Polyethylene Glycols / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12690306.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


41. Dauda MM, Shehu SM: Malignant melanoma: a review. Niger Postgrad Med J; 2005 Jun;12(2):125-30
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma: a review.
  • The incidence of malignant melanoma the most malignant of all skin neoplasms, has doubled within the last 10 years.
  • Controversies still exist in which factors actually determine prognosis, in patients with advanced malignant melanoma.
  • Management has remained even more controversial, with surgical excision, with or without lymphadenectomy, radiotherapy, chemotherapy, laser therapy and more recently immunotherapy and intra-arterial neutron thermal capture therapy, having their proponents and opponents.
  • [MeSH-major] Melanoma
  • [MeSH-minor] Humans. Nigeria / epidemiology. Skin Neoplasms / diagnosis. Skin Neoplasms / epidemiology. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997263.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 42
  •  go-up   go-down


42. Fukunaga T, Soejima H, Sugamura K, Kojima S, Sugiyama S, Sakamoto T, Yoshimura M, Tanoue T, Kageshita T, Ono T, Ogawa H: Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report. J Cardiol; 2006 Apr;47(4):191-5
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report.
  • A 61-year-old woman with stage IV malignant melanoma suffered acute myocardial infarction during the third course of chemotherapy with cisplatin, dacarbazine, nimustine hydrochloride and tamoxifen citrate, despite no serious problem occurring during the first and second courses of chemotherapy.
  • Since this patient, excluding menopause, had no significant risk factor for coronary heart disease before the start of chemotherapy, the infarction was likely to be attributable to the chemotherapy regimen.
  • Chemotherapy should be used cautiously in patients with coronary risk factors before treatment is begun.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cisplatin / adverse effects. Melanoma / drug therapy. Myocardial Infarction / chemically induced. Skin Neoplasms / drug therapy
  • [MeSH-minor] Calcinosis / complications. Coronary Artery Disease / complications. Dacarbazine / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Nimustine / administration & dosage. Tamoxifen / administration & dosage

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637253.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 0S726V972K / Nimustine; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Chrissos DN, Stougiannos PN, Mytas DZ, Katsaros AA, Andrikopoulos GK, Kallikazaros IE: Multiple cardiac metastases from a malignant melanoma. Eur J Echocardiogr; 2008 May;9(3):391-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cardiac metastases from a malignant melanoma.
  • Metastatic tumors in the pericardium or the heart are more common than primary tumors and their incidence has increased during the last decades due to the prolonged survival of patients with cancer and the increased prevalence of the disease in the general population.
  • He had a history of a malignant skin melanoma surgically removed 4 years ago.
  • Malignant metastasis was confirmed by pericardiocentesis and, although treatment with chemotherapy was promptly initiated, the patient died 4 months later.
  • Despite the difficulty in clinical diagnosis of cardiac melanoma, early detection has important therapeutic and prognostic implications.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Melanoma / ultrasonography. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347051.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Nieder C, Grosu AL, Astner S, Thamm R, Molls M: Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Radiat Oncol; 2006;1:19
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors.
  • Patients with brain metastases represent a heterogeneous group where selection of the most appropriate treatment depends on many patient- and disease-related factors.
  • Whole-brain radiotherapy in combination with chemotherapy has recently gained increasing attention and is hoped to augment the palliative effect of whole-brain radiotherapy alone and to extend survival in certain subsets of patients with controlled extracranial disease and good performance status.
  • The randomized trials of whole-brain radiotherapy vs. whole-brain radiotherapy plus chemotherapy suggest that this concept deserves further study, although they failed to improve survival.
  • Sometimes, the question arises whether patients with newly detected brain metastases and the indication for systemic treatment of extracranial disease can undergo standard systemic chemotherapy with the option of deferred rather than immediate radiotherapy to the brain.
  • The literature contains numerous small reports on this issue, mainly in malignant melanoma, breast cancer, lung cancer and ovarian cancer, but very few sufficiently powered randomized trials.
  • With chemotherapy alone, response rates were mostly in the order of 20-40%.
  • The choice of chemotherapy regimen is often complicated by previous systemic treatment and takes into account the activity of the drugs in extracranial metastatic disease.
  • Our systematic literature review suggests that both chemotherapy and radiochemotherapy for newly diagnosed brain metastases need further critical evaluation before standard clinical implementation.
  • A potential chemotherapy indication might exist as palliative option for patients who have progressive disease after radiotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy / methods. Disease Progression. Disease-Free Survival. Humans. Medical Oncology / methods. Neoplasm Metastasis. Radiotherapy / methods. Randomized Controlled Trials as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Jan;12(1):59-67 [11249050.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):249-54 [11300333.001]
  • [Cites] Onkologie. 2001 Jun;24(3):256-60 [11455218.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1724-9 [12175688.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3644-50 [12202665.001]
  • [Cites] Oncology. 2003;64(1):28-35 [12457029.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):97-103 [12569292.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2529-36 [12829672.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):452-64 [12957257.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2101-7 [15169796.001]
  • [Cites] Melanoma Res. 2004 Aug;14(4):289-94 [15305160.001]
  • [Cites] Lung Cancer. 2004 Oct;46(1):107-11 [15364138.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):1873-8 [2224783.001]
  • [Cites] Neurosurgery. 1991 Feb;28(2):201-5 [1997887.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Radiologe. 1995 Nov;35(11):816-21 [8657883.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1063-70 [9060546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):25-30 [9300736.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3563-9 [9817276.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):73-86 [9874189.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):549-58 [10078636.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1599-605 [10193952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):185-91 [15629610.001]
  • [Cites] Strahlenther Onkol. 2005 Jan;181(1):20-5 [15660189.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):61-5 [15719277.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):73-81 [15719279.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2590-7 [15861414.001]
  • [Cites] Oncol Rep. 2005 Sep;14(3):733-6 [16077984.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(1):34-9 [16010592.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):106-14 [16314619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):898-903 [16338097.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3400-8 [11013281.001]
  • (PMID = 16800900.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC1523351
  • [General-notes] NLM/ Original DateCompleted: 20070802
  •  go-up   go-down


45. Tsuji M, Nakai N, Ueda E, Takenaka H, Katoh N, Kishimoto S: Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease. J Dermatol; 2010 May;37(5):484-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease.
  • The plantar lesion was a 15-mm ulcerated nodule located at the center of a 25-mm atypical pigmentation region; the nodule was clinically suspected to be a malignant melanoma.
  • There was no evidence of metastasis in the computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography scans.
  • Melanoma cells were identified in the sentinel lymph nodes, and left radical lymph node dissection was performed after a course of neoadjuvant chemotherapy.
  • All the lymph nodes that were resected during the second operation tested negative for melanomas, and the plantar lesion was diagnosed as a stage IIIB malignant melanoma (pT4b, Na2, M0).
  • Thereafter, we administrated four courses of chemotherapy, and 8 months after the operation, there was no evidence of recurrence or metastatic lesions.
  • We present a case report of double cancer: a plantar malignant melanoma and vulvar EMPD, and also discuss the possible genetic mutations responsible for these two tumors.
  • [MeSH-major] Foot Diseases / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Paget Disease, Extramammary / pathology. Skin Neoplasms / pathology. Vulvar Neoplasms / pathology


46. Nishihara M, Sasayama T, Kondoh T, Tanaka K, Kohmura E, Kudo H: Long-term survival after surgical resection of primary spinal malignant melanoma. Neurol Med Chir (Tokyo); 2009 Nov;49(11):546-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after surgical resection of primary spinal malignant melanoma.
  • He had a history of primary spinal intramedullary malignant melanoma at the T6 level 18 years previously, which had remained stable for 18 years.
  • Magnetic resonance imaging revealed central nervous system (CNS) dissemination of malignant melanoma.
  • Whole brain radiation therapy (30 Gy), local radiation therapy (15 Gy), and routine intrathecal injection of interferon beta were performed.
  • The progression of CNS dissemination of malignant melanoma was controlled without neurological deterioration for 38 months.
  • The prognosis for primary CNS malignant melanomas better than that for cutaneous melanoma.
  • The unusually long survival in the present case indicates the effectiveness of the combined radiotherapy and interferon therapy.
  • [MeSH-major] Melanoma / mortality. Melanoma / therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy / methods. Disease Progression. Disease-Free Survival. Headache / etiology. Humans. Interferon-beta / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiotherapy. Prognosis. Radiotherapy / methods. Spinal Cord / pathology. Spinal Cord / physiopathology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940408.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 77238-31-4 / Interferon-beta
  •  go-up   go-down


47. Franke W, Neumann NJ, Ruzicka T, Schulte KW: [Adjuvant therapy of malignant melanoma]. Praxis (Bern 1994); 2001 Feb 22;90(8):301-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant therapy of malignant melanoma].
  • [Transliterated title] Die adjuvante Therapie des malignen Melanoms.
  • Malignant melanoma is resected with curative intent in 80-85% of the patients.
  • Single agent chemotherapy with DTIC is effective as combination regimen, however does not significantly improve the relapse-free interval respectively the overall survival or quality of life.
  • Several attempts with other adjuvant treatment modalities (e.g.
  • The best results of adjuvant treatment in high-risk resected melanoma were published in 1996 by Kirkwood, who used interferon-alfa 2b.
  • It does represent the current standard adjuvant treatment.
  • [MeSH-major] Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] BCG Vaccine / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Dacarbazine / therapeutic use. Humans. Interferon-alpha / therapeutic use. Neoplasm Staging. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11256332.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Interferon-alpha; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 27
  •  go-up   go-down


48. Thies A, Pfüller U, Schachner M, Horny HP, Molls I, Schumacher U: Binding of mistletoe lectins to cutaneous malignant melanoma: implications for prognosis and therapy. Anticancer Res; 2001 Jul-Aug;21(4B):2883-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Binding of mistletoe lectins to cutaneous malignant melanoma: implications for prognosis and therapy.
  • However, no data concerning the three mistletoe lectins (MLs) and the spread of malignant melanoma have been published.
  • MATERIALS AND METHODS: The binding status of ML-I, -II and -III was histochemically assessed in 100 malignant melanomas and correlated with metastasis in a 10 year follow-up period.
  • CONCLUSION: Since ML-I is specific for galactose, high density galactose expression in malignant melanoma is a predictor of poor prognosis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / metabolism. Lectins / metabolism. Melanoma / metabolism. Plant Preparations. Plant Proteins. Skin Neoplasms / metabolism. Toxins, Biological / metabolism
  • [MeSH-minor] Adjuvants, Immunologic / pharmacology. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Killer Cells, Natural / drug effects. Killer Cells, Natural / pathology. Life Tables. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Ribosome Inactivating Proteins, Type 2

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11712781.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents, Phytogenic; 0 / Lectins; 0 / Plant Preparations; 0 / Plant Proteins; 0 / Ribosome Inactivating Proteins, Type 2; 0 / Toxins, Biological; 0 / mistletoe lectin I; 0 / ribosome inactivating protein, Viscum
  •  go-up   go-down


49. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR: Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol; 2007 Jun 20;25(18):2540-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
  • PURPOSE: To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma.
  • PATIENTS AND METHODS: Patients with unresectable stage III or IV cutaneous melanoma who had no prior systemic chemotherapy were randomly assigned to receive either 40 to 80 mg LM and 125 mg/m2 TMZ or 200 mg/m2 TMZ on days 1 through 5 of each 28-day treatment cycle.
  • Drugs were administered orally for up to six cycles of treatment.
  • Patients on TMZ alone were offered LM/TMZ at progression, if fit enough to receive treatment.
  • Median time to disease progression was 65.5 days for LM/TMZ and 68 days for TMZ.
  • All treatments were well tolerated, although hematologic and gastrointestinal adverse events were common.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Enzyme Inhibitors / administration & dosage. Melanoma / drug therapy. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Purines. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577032.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Purines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; S79265T71M / lomeguatrib
  •  go-up   go-down


50. Dixon A: Melanoma with cutaneous melanoma secondaries. Aust Fam Physician; 2006 Nov;35(11):871-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma with cutaneous melanoma secondaries.
  • Nearby, two similar lesions were apparently separated by normal skin.
  • Histology confirmed these were malignant melanoma.
  • The 'normal' skin between lesions also demonstrated melanoma beneath the surface.
  • At its thickest, this melanoma was a (Breslow) 2.56 mm, Clark 4 lesion.
  • The tumour was excised with a minimum 20 mm margin of normal skin.
  • Given the depth of the tumour, Mr HG was co-managed with the Victoria Melanoma Unit.
  • There are no radiotherapy or chemotherapy programs that have been demonstrated to improve survival in patients with an advanced primary melanoma such as this.
  • [MeSH-major] Lung Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Treatment Refusal

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aust Fam Physician. 2007 Jul;36(7):487-8; author reply 488-9 [17672023.001]
  • (PMID = 17099806.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


51. Hayes AJ, Clark MA, Harries M, Thomas JM: Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg; 2004 Jun;91(6):673-82
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of in-transit metastases from cutaneous malignant melanoma.
  • BACKGROUND: In-transit metastases from cutaneous malignant melanoma (cutaneous or subcutaneous deposits between the primary melanoma and regional lymph nodes) represent late-stage disease, and their treatment should be tailored accordingly.
  • This article reviews the pathology, clinical significance and treatment options for in-transit disease from melanoma.
  • METHODS: An initial Medline search was undertaken using the keywords 'melanoma and in-transit' and 'melanoma and non-nodal regional recurrence'.
  • The method of treatment should be tailored to the extent of cutaneous disease.
  • The first line of treatment remains complete excision with negative histopathological margins.
  • Carbon dioxide laser therapy is valuable for multiple small cutaneous deposits.
  • Systemic chemotherapy has response rates of about 25 per cent and is reserved for patients for whom surgery is no longer feasible.
  • [MeSH-major] Melanoma / secondary. Melanoma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Amputation. Chemotherapy, Cancer, Regional Perfusion. Humans. Laser Therapy / methods. Lymphatic Metastasis. Neoplasm Recurrence, Local / etiology. Risk Factors. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15164434.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Ogawa T, Nakayama B, Hasegawa Y, Fujimoto Y, Kohmura T, Matsuura H, Miyata H: Treatment of malignant melanoma of the lower eyelid using anterolateral thigh flap. Auris Nasus Larynx; 2000 Jan;27(1):79-82
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant melanoma of the lower eyelid using anterolateral thigh flap.
  • Malignant melanoma is a poor prognostic disease with the potential for high mortality despite early diagnosis and currently available treatment.
  • We reported a case of malignant melanoma of the left lower eyelid, and presented the surgical excision and reconstruction using anterolateral thigh flap for skin defect.
  • It is evident that comprehensive treatment using radical surgery and adjuvant chemotherapy is necessary for cutaneous malignant melanoma of head and neck areas.
  • [MeSH-major] Eyelid Neoplasms / surgery. Melanoma / surgery. Skin Transplantation / methods. Surgical Flaps. Thigh
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Male. Postoperative Care. Reconstructive Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10648074.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


53. Bujas T, Pavić I, Prus A, Marusić Z, Balicević D: Primary oral malignant melanoma: case report. Acta Clin Croat; 2010 Mar;49(1):55-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oral malignant melanoma: case report.
  • Primary oral malignant melanoma usually presents as a dark brown or black lesion.
  • It is a rare malignancy, accounting for less than 1% of all melanomas and 1.6% of all head and neck malignancies, thus forming up to 0.5% of all oral malignancies in the world literature.
  • In general, the prognosis of oral melanoma is poor and worse than that of cutaneous melanoma.
  • The preferred treatment is radical surgery alone or in combination with radiotherapy, chemotherapy, immunotherapy and immunomodulatory agents.
  • A case is presented of a large malignant melanoma of oral cavity, noticed six months before initial biopsy and by history described as a rapidly growing mass.
  • [MeSH-major] Melanoma / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20635585.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


54. Facchetti F, Monzani E, La Porta CA: New perspectives in the treatment of melanoma: anti-angiogenic and anti-lymphangiogenic strategies. Recent Pat Anticancer Drug Discov; 2007 Jan;2(1):73-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New perspectives in the treatment of melanoma: anti-angiogenic and anti-lymphangiogenic strategies.
  • Melanoma is a significant, worldwide growing public health burden.
  • Single-agent chemotherapy or immunotherapy remains the treatment of election for this disease when systemic therapy is offered.
  • Malignant melanoma of the skin is distinguished by its capability to early metastatic spread by means of lymphatic vessels to regional lymph nodes.
  • Herein new accomplishments on the role of lymphangiogenesis and of angiogenesis in cutaneous melanoma will be discussed, together with the possible application of these discoveries in developing prognostic and therapeutic tools in melanoma metastasis.
  • Furthermore, the present review will summarize the main angiogenic inhibitors reported in the recent patents (2003-2005), with special emphasis on the aspects which have important implications for the prognosis and the treatment of human melanomas.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphangiogenesis / drug effects. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221054.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 89
  •  go-up   go-down


55. Wcisło G, Szczylik C: [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting]. Pol Merkur Lekarski; 2003 Jul;15(85):5-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
  • [Transliterated title] Leczenie adiuwantowe interferonem chorych na czerniaka złośliwego skóry.
  • Malignant melanoma still remains a challenge as an increase of the malignant disease incidence is noted.
  • Five years after removal of the primary lesion, the recurrence of malignant melanoma is observed in 55-80% of patients at high risk for the recurrence.
  • These results point to the need of searching for optimal adjuvant treatment.
  • Standard cytostatics are of no use due to lacking effectiveness in adjuvant treatment.
  • Early results of clinical trials (15-20% of objective responses) with interferon in the treatment of advanced cutaneous malignant melanoma have created the foundations for the determination of the role of this cytokine in adjuvant treatment.
  • Adjuvant therapy with low doses of interferon is ineffective with respect to neither overall survival time nor disease-free time while high-dose interferon immunotherapy increases the overall survival time (as confirmed by two randomised trials out of three trials conducted) and disease-free survival.
  • For this reason, high-dose interferon immunotherapy should be administered to cutaneous malignant melanoma patients at high risk for disease recurrence.
  • [MeSH-major] Antiviral Agents / therapeutic use. Interferons / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14593950.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Editorial; English Abstract; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  • [Number-of-references] 19
  •  go-up   go-down


56. Meyer T, Göhl J: [Regional chemotherapy--perfusion of the extremities]. Kongressbd Dtsch Ges Chir Kongr; 2001;118:200-4
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regional chemotherapy--perfusion of the extremities].
  • [Transliterated title] Regionale Chemotherapie--Extremitätenperfusion.
  • Hyperthermic isolated limb perfusion with cytostatic drugs (HILP) is indicated in locoregional recurrences of malignant melanoma of the limbs.
  • As a neoadjuvant treatment it is also used for non-curatively resectable soft tissue sarcoma or their recurrences on the extremities.
  • Up to now, melphalan is still the standard drug in HILP for malignant melanoma.
  • The combination of TNF with other drugs than melphalan could possibly further improve results of HILP in sarcoma patients.
  • The high rate of local recurrences of malignant melanoma after HILP poses an unsolved problem yet.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11824246.001).
  • [Journal-full-title] Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress
  • [ISO-abbreviation] Kongressbd Dtsch Ges Chir Kongr
  • [Language] GER
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


57. Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, Roberts MS: Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer; 2001 Jul 20;85(2):157-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
  • This study sought to use a microdialysis technique to relate clinical and biochemical responses to the time course of melphalan concentrations in the subcutaneous interstitial space and in tumour tissue (melanoma, malignant fibrous histiocytoma, Merkel cell tumour and osteosarcoma) in patients undergoing regional chemotherapy by Isolated Limb Infusion (ILI).
  • 19 patients undergoing ILI for treatment of various limb malignancies were monitored for intra-operative melphalan concentrations in plasma and, using microdialysis, in subcutaneous and tumour tissues.
  • There was no significant difference between drug peak and mean concentrations in interstitial and tumour tissue, indicating that there was no preferential uptake of melphalan into the tumours.
  • The time course of melphalan in the microdialysate could be described by a pharmacokinetic model which assumed melphalan distributed from the plasma into the interstitial space.
  • Tumour response in the whole group to treatment was partial response: 53.8% (n = 7); complete response: 33.3% (n = 5); no response: 6.7% (n = 1).
  • There was a significant association between tumour response and melphalan concentrations measured over time in subcutaneous microdialysate (P< 0.01).
  • It is concluded that microdialysis is a technique well suited for measuring concentrations of cytotoxic drug during ILI.
  • The possibility of predicting actual concentrations of cytotoxic drug in the limb during ILI using our model opens an opportunity for improved drug dose calculation.
  • The combination of predicting tissue concentrations and monitoring in microdialysate of subcutaneous tissue could help optimise ILI with regard to post-operative limb morbidity and tumour response.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Melphalan / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Merkel Cell / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Humans. Melanoma / drug therapy. Microdialysis. Middle Aged. Osteosarcoma / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Feb;10(1):47-54 [10711640.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Oct;18(10):905-10 [6891640.001]
  • [Cites] Am J Physiol. 1984 May;246(5 Pt 2):R665-77 [6720989.001]
  • [Cites] J Pharmacokinet Biopharm. 1988 Feb;16(1):41-83 [3373419.001]
  • [Cites] J Intern Med. 1991 Oct;230(4):365-73 [1919432.001]
  • [Cites] Eur J Cancer. 1992;28A(11):1811-3 [1389515.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):151-3 [8018528.001]
  • [Cites] J Pathol. 1995 Jul;176(3):279-87 [7674090.001]
  • [Cites] Melanoma Res. 1995 Dec;5(6):425-31 [8589617.001]
  • [Cites] Cancer Lett. 1996 Feb 6;99(2):225-31 [8616828.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):920-4 [8611407.001]
  • [Cites] J Chromatogr B Biomed Appl. 1995 Nov 17;673(2):267-79 [8611961.001]
  • [Cites] Br J Surg. 1996 Oct;83(10):1319-28 [8944445.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):267-72 [8996531.001]
  • [Cites] Melanoma Res. 1997 Feb;7(1):19-26 [9067961.001]
  • [Cites] Melanoma Res. 1997 Jun;7(3):252-64 [9195565.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2598-601 [9205062.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):903-7 [9267277.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):238-47 [9548607.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2982-5 [9679959.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2906-12 [9738557.001]
  • [Cites] Electrophoresis. 1998 Nov;19(16-17):2981-5 [9870399.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):522-30 [10235581.001]
  • [Cites] Ann Pharmacother. 1999 Jun;33(6):730-8 [10410188.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1000-3 [10737379.001]
  • (PMID = 11461070.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2364039
  •  go-up   go-down


58. Négrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Doré JF, Dorval T, Garbay JR, Vilmer C: [Standards, Options and Recommendations (SOR): clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Fédération Nationale des Centres de Lutte Contre le Cancer]. Bull Cancer; 2000 Feb;87(2):173-82
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards, Options and Recommendations (SOR): clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Fédération Nationale des Centres de Lutte Contre le Cancer].
  • [Transliterated title] Standards, Options et Recommandations (SOR) pour la prise en charge des patients atteints de mélanome cutané.
  • CONTEXT: The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French Cancer Centres and specialists from French Public Universities, General Hospitals and Private Clinics.
  • The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients.
  • The methodology is based on literature systematic review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.
  • OBJECTIVES: To develop clinical practice guidelines according to the definitions of Standards, Options and Recommendations for the management of patients with cutaneous melanoma.
  • Once the guidelines were defined, the document was submitted for review to national and international independent reviewers and to the medical committees of the 20 French Cancer Centres.
  • RESULTS: The main recommendations for the management of cutaneous melanoma (CM) are:.
  • 1) The primary prevention of melanoma is based on a reduction in exposure to ultraviolet rays (solar or artificial).
  • 2) The diagnosis of CM requires the surgical removal and histological examination of the lesion (standard).
  • 3) The pathological report must include the diagnosis of primary malignant melanoma, the maximum thickness of the tumour in millimeters (Breslow), the clearance of surgical margins, the level of invasion (Clark), the presence and extension of regression and the presence of any ulceration (standard).
  • 4) The standard treatment of a primary melanoma without lymph node involvement is based on surgery that must ensure adequate margins depending on the thickness of the tumour (standard, level of evidence B).
  • 5) After surgery of a stage I melanoma, there is no indication for additional treatment outside a prospective therapeutic study (standard, level of evidence B, French Consensus Conference).
  • 6) For a local recurrence without node involvement, in the absence of other metastases, surgical excision is the standard treatment.
  • There is no indication for additional treatment outside a prospective therapeutic study (standard, level of evidence B).
  • 8) There is no standard therapeutic strategy for metastatic melanoma.
  • Conventional palliative treatment is chemotherapy with dacarbazine (level of evidence B).
  • Clinical surveillance and self-detection are indicated in all cases throughout life (standard).
  • [MeSH-major] Melanoma / pathology. Melanoma / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10705288.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] FRANCE
  •  go-up   go-down


59. Neuber K, Reinhold U, Deutschmann A, Pföhler C, Mohr P, Pichlmeier U, Baumgart J, Hauschild A: Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Melanoma Res; 2003 Feb;13(1):81-5
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
  • The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients.
  • Thirty-one patients with measurable stage IV malignant melanoma and prior chemotherapy with a dacarbazine-containing regimen were included.
  • Patients were evaluated for tumour response, survival time and toxicity.
  • Five patients (19%) showed no change and 21 had progressive disease after treosulfan treatment.
  • The median time to progression was 1.8 months (95% confidence interval [CI] 1.6-2.1 months) and the median overall survival was 6.5 months (95% CI 3.1-10 months).
  • The non-haematological toxicity of this outpatient regimen was mild.
  • In conclusion, intravenous treosulfan treatment does not induce objective response rates when used as a second-line treatment of metastatic malignant melanoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / analogs & derivatives. Busulfan / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Salvage Therapy. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TREOSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12569289.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan
  •  go-up   go-down


60. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev; 2007;(1):CD005413
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
  • BACKGROUND: Malignant melanoma, one of the most aggressive of all skin cancers, is increasing in incidence throughout the world.
  • Surgery remains the cornerstone of curative treatment in earlier stages.
  • Metastatic disease is incurable in most affected people, because melanoma does not respond to most systemic treatments.
  • The combination of chemotherapy and immunotherapy has been reported to improve treatment results, but it is still unclear whether evidence exists to support this choice, compared with chemotherapy alone.
  • OBJECTIVES: To compare the effects of therapy with chemotherapy and immunotherapy (chemoimmunotherapy) versus chemotherapy alone in people with metastatic malignant melanoma.
  • SEARCH STRATEGY: We searched the Cochrane Skin Group Specialised Register (14 February 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2005), MEDLINE (2003 to 30 January 2006 ), EMBASE (2003 to 20 July 2005) and LILACS (1982 to 20 February 2006).
  • SELECTION CRITERIA: All randomised controlled trials that compared the use of chemotherapy versus chemoimmunotherapy on people of any age, diagnosed with metastatic melanoma.
  • Quality assessment included an evaluation of various components associated with biased estimates of treatment effect.
  • Whenever possible, a meta-analysis was performed on the extracted data, in order to calculate a weighed treatment effect across trials.
  • We found evidence of an increase of objective response rates in people treated with chemoimmunotherapy, in comparison with people treated with chemotherapy.
  • We found no difference in survival to support the addition of immunotherapy to chemotherapy in the systemic treatment of metastatic melanoma, with a hazard ratio of 0.89 (95% CI 0.72 to 1.11, p=0.31).
  • Additionally, we found increased hematological and non-hematological toxicities in people treated with chemoimmunotherapy.
  • AUTHORS' CONCLUSIONS: We failed to find any clear evidence that the addition of immunotherapy to chemotherapy increases survival of people with metastatic melanoma.
  • Further use of combined immunotherapy and chemotherapy should only be done in the context of clinical trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy / methods. Humans. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253556.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  • [Number-of-references] 63
  •  go-up   go-down


61. Feun LG, Savaraj N, Hurley J, Marini A, Lai S: A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer; 2000 Feb 1;88(3):584-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma.
  • BACKGROUND: The aim of the current trial was to assess the efficacy and toxicity of weekly intravenous vinorelbine tartrate with daily oral tamoxifen in the treatment of patients with advanced or metastatic malignant melanoma.
  • Tamoxifen, 10 mg orally, twice a day was administered daily starting on Day 1 of chemotherapy with vinorelbine tartrate.
  • Thirty patients had cutaneous melanoma with metastases and 1 patient had ocular melanoma with metastases.
  • Eight patients had received prior chemotherapy.
  • RESULTS: Of the 30 evaluable patients with cutaneous melanoma, 6 achieved a partial response, for an overall response rate of 20% (95% confidence interval, 7-38%).
  • There was no response in the patient with ocular melanoma.
  • Major sites of response include the adrenal gland, lung, tonsil, and cutaneous/subcutaneous tissues.
  • CONCLUSIONS: Weekly intravenous vinorelbine tartrate plus daily oral tamoxifen appears to be active in the treatment of patients with malignant melanoma.
  • Further clinical trials in malignant melanoma patients treated with vinorelbine tartrate and tamoxifen appear warranted.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Tamoxifen / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Confidence Intervals. Disease Progression. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Fatigue / chemically induced. Female. Follow-Up Studies. Humans. Infusions, Intravenous / adverse effects. Male. Middle Aged. Neoplasm Staging. Pain / chemically induced. Paresthesia / chemically induced. Remission Induction

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10649251.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 094ZI81Y45 / Tamoxifen; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


62. Chang JW: Cutaneous melanoma: Taiwan experience and literature review. Chang Gung Med J; 2010 Nov-Dec;33(6):602-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous melanoma: Taiwan experience and literature review.
  • Malignant melanoma is a rare disease in Taiwan with an incidence rate of 0.65/100,000.
  • Excessive exposure to ultraviolet radiation is not associated with most Taiwanese melanoma cases.
  • Acral lentiginous melanoma comprises 58% of cutaneous melanoma.
  • Surgery, including resection of the primary melanoma, sentinel lymph nodes that may harbor microscopic metastasis, clinically abnormal lymph nodes, and selected distant metastases, is the most important treatment.
  • Lymphatic mapping and sentinel lymph node biopsy has changed the clinical stage in 22.2% of our patients.
  • In the past, chemotherapy alone was the most common treatment modality for metastatic disease.
  • Recently biochemotherapy has been more commonly utilized to treat patients with metastatic melanoma.
  • [MeSH-major] Melanoma. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199605.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


63. Nakamura T, Ide H: [Malignant melanoma of the alimentary tract]. Gan To Kagaku Ryoho; 2003 May;30(5):619-25
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma of the alimentary tract].
  • We reviewed case reports of malignant melanoma in the alimentary tract and discussed the diagnosis and treatment.
  • Cases of malignant melanoma in the alimentary tract have mostly originated from the esophagus and an anorectal lesion.
  • Malignant melanoma of the alimentary tract might be more aggressive than that of the skin.
  • A combined modality treatment including progressive chemotherapy and biotherapy is expected to improve the prognosis of these patients.
  • [MeSH-major] Anus Neoplasms. Esophageal Neoplasms. Melanoma. Rectal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Nimustine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795092.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; DAV protocol
  • [Number-of-references] 39
  •  go-up   go-down


64. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Bröcker EB, Neumann C, Rünger TM, Schuler G, von den Driesch P, Müller I, Paul E, Patzelt T, Reitz M: Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer; 2002 Jan 21;86(2):179-84
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
  • The purpose of this randomized trial was to evaluate the efficacy of combination chemoimmunotherapy compared with chemotherapy alone.
  • In those patients who received sequential immunotherapy, each cycle of chemotherapy was followed by outpatient s.c.
  • The overall response rate of patients treated with the combination of chemotherapy and IL-2/IFN-alpha was 34.3% with seven complete responses (10.9%) and 15 partial responses (23.4%).
  • In patients treated with chemotherapy, only, the overall response rate was 29.9% with eight complete responses (13.3%) and 10 partial responses (16.6%).
  • There was no significant difference in median progression free survival (0 months vs 4 months) and in median overall survival (12 months vs 13 months) for combined chemoimmunotherapy and for chemotherapy, respectively.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon-alpha / pharmacology. Interleukin-2 / pharmacology. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Prospective Studies. Tamoxifen / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 The Cancer Research Campaign
  • [Cites] Br J Cancer. 2000 Mar;82(6):1158-62 [10735499.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):968-75 [10071291.001]
  • [Cites] J Invest Dermatol. 1990 Dec;95(6 Suppl):188S-192S [2124246.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1338-43 [1634924.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1919-26 [1280673.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):617-26 [8120562.001]
  • [Cites] JAMA. 1994 Mar 23-30;271(12):907-13 [8120958.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1553-60 [8040667.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):876-81 [7646914.001]
  • [Cites] Melanoma Res. 1995 Aug;5(4):273-6 [7496164.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2083-90 [8683240.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):827-35 [8922197.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6):744-53 [8970597.001]
  • [Cites] Cancer J Sci Am. 1997 Dec;3 Suppl 1:S9-15 [9457387.001]
  • [Cites] Cancer J Sci Am. 1997 Dec;3 Suppl 1:S29-34 [9457390.001]
  • [Cites] Cancer. 1998 May 1;82(9):1677-81 [9576288.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1280-6 [9579834.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1743-51 [9586887.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1752-9 [9586888.001]
  • [Cites] Br J Cancer. 1998 Oct;78(8):1076-80 [9792153.001]
  • [Cites] Melanoma Res. 2001 Apr;11(2):189-96 [11333130.001]
  • (PMID = 11870502.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 094ZI81Y45 / Tamoxifen; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ PMC2375173
  •  go-up   go-down


65. Janik JE, Miller LL, Korn EL, Stevens D, Curti BD, Smith JW 2nd, Sznol M, Conlon KC, Sharfman W, Urba WJ, Gause BL, Longo DL: A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood; 2001 Apr 1;97(7):1942-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
  • We conducted a phase II randomized trial of recombinant granculocyte-macrophage colony-stimulating factor (GM-CSF) administered before topotecan chemotherapy to determine whether it could prevent myelosuppression and to determine the antitumor activity of this topoisomerase I inhibitor in 53 patients with metastatic malignant melanoma and renal cell cancer.
  • Patients randomly assigned to receive GM-CSF priming were treated with GM-CSF at 250 microg/m(2) twice daily for 5 days before treatment.
  • The primary analysis was restricted to the protective effects seen during the first cycle of therapy.
  • The protective effects of GM-CSF extended to the second cycle of treatment.
  • Chemotherapy-induced anemia and thrombocytopenia were similar in both groups.
  • One partial response was seen in a patient with melanoma, and one patient with renal cell cancer had complete regression of pulmonary metastases and was rendered disease-free by nephrectomy. (Blood.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Renal Cell / drug therapy. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Kidney Neoplasms / drug therapy. Melanoma / drug therapy. Neutropenia / prevention & control. Skin Neoplasms / drug therapy. Topotecan / adverse effects
  • [MeSH-minor] Anemia / chemically induced. Diabetes Mellitus, Type 1 / complications. Humans. Hypotension / chemically induced. Premedication. Prospective Studies. Remission Induction. Severity of Illness Index. Stroke / etiology. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11264156.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


66. Parker KA, Glaysher S, Polak M, Gabriel FG, Johnson P, Knight LA, Poole M, Narayanan A, Hurren J, Cree IA: The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol; 2010 Nov;63(11):1012-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy.
  • BACKGROUND: Chemotherapy benefits relatively few patients with cutaneous melanoma.
  • The assessment of tumour chemosensitivity by the ATP-based tumour chemosensitivity assay (ATP-TCA) has shown strong correlation with outcome in cutaneous melanoma, but requires fresh tissue and dedicated laboratory facilities.
  • AIM: To examine whether the results of the ATP-TCA correlate with the expression of genes known to be involved in resistance to chemotherapy, based on the hypothesis that the molecular basis of chemosensitivity lies within known drug resistance mechanisms.
  • METHOD: The chemosensitivity of 47 cutaneous melanomas was assessed using the ATP-TCA and correlated with quantitative expression of 93 resistance genes measured by quantitative reverse transcriptase PCR (qRT-PCR) in a Taqman Array after extraction of total RNA from formalin-fixed paraffin-embedded tissue.
  • RESULTS: Drugs susceptible to particular resistance mechanisms showed good correlation with genes linked to these mechanisms using signatures of up to 17 genes.
  • CONCLUSIONS: These data suggest that melanoma chemosensitivity is influenced by known resistance mechanisms, including susceptibility to apoptosis.
  • Use of a candidate gene approach may increase understanding of the mechanisms underlying chemosensitivity to drugs active against melanoma and provide signatures with predictive value.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm / genetics. Melanoma / genetics. Melanoma / secondary. Skin Neoplasms / genetics
  • [MeSH-minor] Adenosine Triphosphate / biosynthesis. Adult. Aged. Aged, 80 and over. Apoptosis / genetics. DNA, Neoplasm / genetics. Drug Screening Assays, Antitumor / methods. Gene Expression Profiling / methods. Genes, Neoplasm. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction / methods


67. Chaudhuri P, Soni S, Sengupta S: Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma. Nanotechnology; 2010 Jan 15;21(2):025102
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma.
  • The incidence of malignant melanoma is increasing at an alarming rate globally.
  • Poor prognosis and extraordinarily low survival rates of malignant melanoma necessitates the development of new chemotherapeutic strategies.
  • In the present study we have demonstrated that the delivery of doxorubicin using a nanotechnology-based platform significantly reduces the systemic toxicity of the drug, keeping unchanged its therapeutic efficacy in a mouse melanoma tumor model.
  • Specifically we modified single-walled carbon nanotubes (CNTs) to conjugate a doxorubicin prodrug via a carbamate linker that cleaves enzymatically to cause temporal release of the active drug.
  • The CNT-doxorubicin conjugate (CNT-Dox) induced time-dependent cell death in B16-F10 melanoma cells in vitro.
  • The nanoparticle was rapidly internalized into the lysosome of melanoma cells and was retained in the subcellular compartment for over 24 h.
  • In an in vivo melanoma model, treatment with the nanotube-doxorubicin conjugate abrogated tumor growth without the systemic side-effects associated with free doxorubicin.
  • Our studies demonstrate that a simple and versatile CNT-based nanovector can be harnessed for the delivery of chemotherapy to melanoma, with increased therapeutic index.
  • [MeSH-major] Doxorubicin / administration & dosage. Doxorubicin / chemistry. Drug Carriers / chemistry. Melanoma / drug therapy. Melanoma / pathology. Nanotubes, Carbon / chemistry
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / chemistry. Cell Line, Tumor. Crystallization / methods. Dose-Response Relationship, Drug. Drug Compounding / methods. Macromolecular Substances / chemistry. Materials Testing. Mice. Mice, Inbred C57BL. Molecular Conformation. Nanomedicine / methods. Surface Properties. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955607.001).
  • [ISSN] 1361-6528
  • [Journal-full-title] Nanotechnology
  • [ISO-abbreviation] Nanotechnology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Macromolecular Substances; 0 / Nanotubes, Carbon; 80168379AG / Doxorubicin
  •  go-up   go-down


68. Chang PN, Yap WN, Lee DT, Ling MT, Wong YC, Yap YL: Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutr Cancer; 2009;61(3):357-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells.
  • To date, the most effective cure for metastatic melanoma remains the surgical resection of the primary tumor.
  • Recently, tocotrienol-rich-fraction has shown antiproliferative effect on cancer cells.
  • To elucidate this anticancer property in malignant melanoma, this study aimed, first, to identify the most potent isomer for eliminating melanoma cells and second to decipher the molecular pathway responsible for its activity.
  • Meanwhile, gamma-tocotrienol treatment also resulted in induction of JNK signaling pathway, and inhibition of JNK activity by selective inhibitor was able to partially block the effect of gamma-tocotrienol.
  • Interestingly, gamma-tocotrienol treatment led to suppression of mesenchymal markers and the restoration of E-cadherin and gamma-catenin expression, which was associated with suppression of cell invasion capability.
  • Furthermore, synergistic effect was observed when cells were cotreated with gamma-tocotrienol and chemotherapy drugs.
  • Together, our results demonstrated for the first time the anti-invasion and chemonsensitization effect of gamma-tocotrienol against human malignant melanoma cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Chromans / pharmacology. Melanoma / drug therapy. Vitamin E / analogs & derivatives
  • [MeSH-minor] Cadherins / physiology. Cell Line, Tumor. Cell Proliferation / drug effects. Dacarbazine / pharmacology. Humans. JNK Mitogen-Activated Protein Kinases / physiology. Neoplasm Invasiveness. Signal Transduction. Taxoids / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373609.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Chromans; 0 / Taxoids; 1406-18-4 / Vitamin E; 15H5577CQD / docetaxel; 4382-43-8 / plastochromanol 8; 7GR28W0FJI / Dacarbazine; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


69. Atzpodien J, Terfloth K, Fluck M, Reitz M: Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol; 2008 Sep;62(4):685-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
  • PURPOSE: The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma.
  • /intrahepatic cisplatin, i.v. gemcitabine, and i.v. treosulfan (CGT) on day 1 and 8 as first-line (n = 1), second-line (n = 9), third-line (n = 1) or fourth-line (n = 1) therapy.
  • Cisplatin, gemcitabine, and treosulfan (CGT)-therapy was repeated every 5 weeks until progression of disease occurred.
  • CONCLUSIONS: Treatment with CGT may lead to disease stabilization and prolonged survival in a substantial proportion of progressive stage IV uveal melanoma patients, even following heavy chemotherapy treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uveal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TREOSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084763.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Bogenrieder T, Weitzel C, Schölmerich J, Landthaler M, Stolz W: Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology; 2002;205(2):174-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
  • Induction of multiple eruptive dermal and atypical melanocytic naevi has frequently been reported in children with malignant haematological diseases and chemotherapy-induced immunosuppression.
  • This is the first report of an adult patient to develop multiple eruptive melanocytic skin lesions while undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Carcinoma / drug therapy. Carcinoma / secondary. Colorectal Neoplasms / pathology. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Hutchinson's Melanotic Freckle / chemically induced. Prodrugs / adverse effects. Skin Neoplasms / diagnosis
  • [MeSH-minor] Administration, Oral. Capecitabine. Fluorouracil. Humans. Male. Melanoma / physiopathology. Middle Aged. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / pathology. Nevus, Pigmented / chemically induced. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12218237.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Malik I, Shaharyar: Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia. J Pak Med Assoc; 2002 Jan;52(1):15-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia.
  • BACKGROUND: Ceftazidime is commonly used as monotherapy of cancer patients with fever and neutropenia.
  • Concern, however, has been raised regarding potential for drug resistance due to its widespread use.
  • PATIENTS AND METHODS: We prospectively treated 49 patients hospitalized for fever (> 38 degrees C) and neutropenia (ANC < or = 500/cmm) with meropenem.
  • RESULTS: Comparison of demographic features between the 2 groups revealed no differences in age, gender, type of neoplasm, number of patients with prior antibiotic use, number of days since chemotherapy, absolute neutrophil count and number of patients previously or already hospitalized.
  • Therapeutic outcome was same between the two groups.
  • Eighty four percent of patients receiving meropenem and 79% receiving ceftazidime required no modification of the initially assigned therapeutic regimen.
  • [MeSH-major] Ceftazidime / therapeutic use. Cephalosporins / therapeutic use. Neutropenia / drug therapy. Thienamycins / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Female. Fever / chemically induced. Fever / drug therapy. Humans. Male. Neoplasms / drug therapy. Prospective Studies

  • Hazardous Substances Data Bank. Meropenem .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11963577.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cephalosporins; 0 / Thienamycins; 9M416Z9QNR / Ceftazidime; FV9J3JU8B1 / meropenem
  •  go-up   go-down


72. Reinhold U: Cutaneous malignant melanoma: from early diagnosis to gene therapy. Bull Mem Acad R Med Belg; 2001;156(3-4):212-6; discussion 216-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignant melanoma: from early diagnosis to gene therapy.
  • Knowledge about diagnostic procedures in melanoma has increased rapidly within the past few years.
  • These new techniques include epiluminescence microscopy and computerized image analysis of pigmented skin lesions, as well as the identification of single tumor cells in normal tissue, such as sentinal lymph node and peripheral blood by molecular approaches.
  • The introduction of polymerase-chain reaction based methods can be regarded as a prototype of this dramatic development that opens up the possibility of clinical use in patients, and of influencing treatment strategies.
  • While early melanoma is highly curable by surgical means, the prognosis of patients with metastatic disease remains poor.
  • A flurry of new treatment strategies are currently in clinical development.
  • These include test-directed chemotherapy, biologic therapy, vaccine therapy, as well as gene therapy.
  • All different therapeutic strategies have to take into account immense resistance and escape mechanisms of malignant melanoma cells, that potentially limit the effectiveness of new treatment concepts.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Genetic Therapy / methods. Genetic Therapy / trends. Humans. Immunologic Factors / therapeutic use. Mass Screening / methods. Mass Screening / trends. Neoplasm Metastasis. Polymerase Chain Reaction / methods. Polymerase Chain Reaction / trends. Prognosis. Survival Analysis. Time Factors. Treatment Outcome. Vaccination / methods. Vaccination / trends

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789400.001).
  • [ISSN] 0377-8231
  • [Journal-full-title] Bulletin et mémoires de l'Académie royale de médecine de Belgique
  • [ISO-abbreviation] Bull. Mem. Acad. R. Med. Belg.
  • [Language] eng
  • [Publication-type] Lectures
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors
  •  go-up   go-down


73. Wang Y, Cen Y, Li Z: [Therapeutic result of operation combined with large-dose of roferon-A for cutaneous malignant melanoma]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Jan;21(1):37-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic result of operation combined with large-dose of roferon-A for cutaneous malignant melanoma].
  • OBJECTIVE: To observe the effects of operation with large-dose of Roferon-A for cutaneous malignant melanoma.
  • METHODS: From January 1998 to December 2005, thirty-three patients with cutaneous malignant melanoma were treated.
  • In 33 patients, nine patients identified as clinical-stage I received singly enlarged-resection to the primary lesion and performed split-thickness skin graft dermoplasty or adjacent skin flap repair; twenty-three patients identified as clinical-stage II received enlarged-resection to the primary lesion and performed proximal lymphaden scavenge as well as received split-thickness skin graft dermoplasty; and one patient identified as clinical-stage III received palliative resection to the primary lesion.
  • RESULTS: There are no recidivation in the 9 patients of clinical-stage I.
  • There are 1 recidivation and 1 quit in all the 23 patients of clinical-stage II.
  • One patient of clinical-stage III died after 18 months of operation.
  • CONCLUSION: The operation combined with large-dose of Roferon-A after operation was a more effective way to treat cutaneous malignant melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Melanoma / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Injections, Intramuscular. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Skin Transplantation. Surgical Flaps. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305002.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


74. Atzpodien J, Morawek L, Fluck M, Reitz M: Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients. Cancer Chemother Pharmacol; 2009 Oct;64(5):901-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
  • PURPOSE: To evaluate the efficacy of bleomycin, vinorelbine, and trofosfamide (BVT) in 28 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma.
  • METHODS: Patients in relapse after first- or second-line therapy received 8 mg/m(2) intravenous (i.v.) bleomycin, 25 mg/m(2) i.v. vinorelbine, on days 1 and 6, each, and oral (p.o.) trofosfamide 60 mg/m(2)/day, days 1-7.
  • BVT therapy was repeated every 5 weeks until progression of disease occurred.
  • RESULTS: Three patients (11%) reached a partial response; 5 (18%) patients showed stable disease, and 20 (71%) patients progressed upon BVT therapy.
  • CONCLUSION: Treatment with BVT was efficient in 29% of pretreated relapsed stage IV cutaneous melanoma patients, with overall good tolerability and safety.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19229537.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide; Q6C979R91Y / vinorelbine
  •  go-up   go-down


75. Martín-Algarra S, Espinosa E, Rubió J, López López JJ, Manzano JL, Carrión LA, Plazaola A, Tanovic A, Paz-Ares L: Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur J Cancer; 2009 Mar;45(5):732-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
  • This phase II clinical trial evaluated the antitumour response of Kahalalide F (KF) 650 microg/m(2) given as a 1-h weekly infusion in advanced malignant melanoma patients, both untreated and those who relapsed or progressed after one line of systemic therapy.
  • Of 24 enrolled patients (median age, 55 years; range, 28-89), 14 patients had been previously treated with chemotherapy or biological therapy.
  • No RECIST responses occurred; five chemotherapy-naïve patients with cutaneous melanoma had disease stabilisation for > or = 3 months; median progression-free survival was 1.7 months (95% CI, 1.2-1.9 months); and median overall survival was 10.8 months (95% CI, 5.0-upper limit not reached).
  • The most common laboratory toxicities were non-cumulative increase of transaminases (ALT/AST) and gamma-glutamyltransferase (GGT).
  • KF was a well-tolerated and safe chemotherapy regimen.
  • Despite a favourable safety profile, this trial was closed after the first stage because of the lack of objective response in patients with malignant melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Depsipeptides / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186051.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 149204-42-2 / kahalalide F
  •  go-up   go-down


76. von Felbert V, Córdoba F, Weissenberger J, Vallan C, Kato M, Nakashima I, Braathen LR, Weis J: Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol; 2005 Mar;166(3):831-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.
  • Interleukin (IL)-6 is a pleiotropic cytokine that has been shown to inhibit the growth of early stage and to promote the proliferation of advanced stage melanoma cells in vitro.
  • In patients with metastasizing melanomas, highly increased IL-6 blood levels correlate with a poor response to chemotherapy and a worse overall prognosis, suggesting that IL-6 promotes melanoma progression in vivo.
  • Here, we analyzed the role of IL-6 in melanoma development and progression in a transgenic mouse model.
  • We bred IL-6-deficient mice with MT-ret transgenic animals predisposed for melanomas.
  • While MT-ret transgenic animals develop severe melanosis of the skin and subcutis and subsequent melanomas at an incidence of 80% during their first year of life, MT-ret mice devoid of IL-6 developed preneoplastic melanosis and consecutive melanomas significantly less frequently (47%; P < 0.05).
  • Immunoblot analysis revealed that ret transgene expression was not reduced in the skin of mice lacking IL-6, indicating that the observed decrease of melanoma incidence and of tumor sizes was not because of a down-regulation of transgene expression.
  • Taken together, these results indicate that IL-6 enhances both the development of melanoma precursor lesions and the subsequent growth of the resulting tumors in the MT-ret model of melanoma development.
  • [MeSH-major] Interleukin-6 / genetics. Interleukin-6 / physiology. Melanoma / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Biopsy. Blotting, Western. Cell Culture Techniques. Cytokines / metabolism. DNA-Binding Proteins / metabolism. Disease Models, Animal. Disease Progression. Down-Regulation. Genotype. Immunoblotting. Immunohistochemistry. Inflammation. Lectins / metabolism. MAP Kinase Signaling System. Mice. Mice, Transgenic. Necrosis. Phosphatidylinositol 3-Kinases / metabolism. Precancerous Conditions. STAT3 Transcription Factor. Signal Transduction. Skin / pathology. Time Factors. Trans-Activators / metabolism. Transgenes

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Neurosci. 1999 Sep;11(9):2995-3004 [10510164.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):115-22 [9049837.001]
  • [Cites] Surg Today. 1997;27(6):534-41 [9306547.001]
  • [Cites] Melanoma Res. 1998 Feb;8(1):24-30 [9508373.001]
  • [Cites] Eur Cytokine Netw. 1998 Jun;9(2):187-92 [9681395.001]
  • [Cites] Oncogene. 1998 Oct 8;17(14):1885-8 [9778055.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1405-9 [9816314.001]
  • [Cites] Br J Dermatol. 1998 Sep;139(3):415-21 [9767285.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):63-73 [9874564.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1257-66 [9880494.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):1023-32 [10023678.001]
  • [Cites] J Invest Dermatol. 2000 Feb;114(2):343-8 [10651996.001]
  • [Cites] J Neurosci Res. 1999 Feb 15;55(4):411-22 [10723052.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2000;35(1):35-70 [10755665.001]
  • [Cites] Exp Hematol. 2000 Nov;28(11):1239-49 [11063872.001]
  • [Cites] Breast Cancer Res. 2000;2(2):86-90 [11250696.001]
  • [Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]
  • [Cites] J Invest Dermatol. 2001 Jul;117(1):132-40 [11442760.001]
  • [Cites] Oncogene. 2001 Sep 20;20(42):5991-6000 [11593406.001]
  • [Cites] Oncogene. 2001 Nov 8;20(51):7536-41 [11709725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1509-14 [11805288.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] Biochim Biophys Acta. 2002 Nov 11;1592(3):323-43 [12421676.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8404-13 [12466961.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):655-63 [12547723.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):4093-100 [12553038.001]
  • [Cites] J Neurosci. 2003 Mar 1;23(5):1730-41 [12629177.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1517-27 [12629515.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Mar;62(3):315-28 [12638735.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4092-101 [12821943.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3607-22 [15082758.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3308-16 [15064729.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Nature. 1977 Mar 3;266(5597):63-4 [758007.001]
  • [Cites] J Invest Dermatol. 1991 Feb;96(2):180-5 [1899443.001]
  • [Cites] J Invest Dermatol. 1991 Jul;97(1):97-100 [2056197.001]
  • [Cites] EMBO J. 1991 Nov;10(11):3167-75 [1915289.001]
  • [Cites] Immunology. 1992 Jan;75(1):92-8 [1371497.001]
  • [Cites] Exp Hematol. 1992 May;20(4):395-400 [1568457.001]
  • [Cites] Lymphokine Cytokine Res. 1992 Jun;11(3):161-6 [1391235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9215-9 [1409627.001]
  • [Cites] J Cell Biol. 1993 Mar;120(5):1281-8 [8436594.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):98-109 [8318501.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):853-7 [7509778.001]
  • [Cites] Nature. 1994 Mar 24;368(6469):339-42 [8127368.001]
  • [Cites] Arch Dermatol Res. 1994;286(1):62-8 [8141614.001]
  • [Cites] Br J Cancer. 1994 May;69(5):911-3 [8180022.001]
  • [Cites] Melanoma Res. 1995 Feb;5(1):41-7 [7734955.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2200-5 [7743524.001]
  • [Cites] Cytokine. 1995 Feb;7(2):142-9 [7780033.001]
  • [Cites] J Neurosci Res. 1995 Apr 15;40(6):826-35 [7629895.001]
  • [Cites] Hum Gene Ther. 1995 Jun;6(6):805-11 [7548280.001]
  • [Cites] Int J Immunopharmacol. 1996 Feb;18(2):167-72 [8799367.001]
  • [Cites] Melanoma Res. 1996 Jun;6(3):191-201 [8819122.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):160-8 [10096249.001]
  • [Cites] Melanoma Res. 1999 Apr;9(2):181-8 [10380941.001]
  • [Cites] Oncogene. 1999 Jun 24;18(25):3742-53 [10391682.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • (PMID = 15743795.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / Interleukin-6; 0 / Lectins; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, mouse; 0 / Trans-Activators; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC1602365
  •  go-up   go-down


77. Pawlik TM, Sondak VK: Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol; 2003 Mar;45(3):245-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma: current state of primary and adjuvant treatment.
  • Metastatic malignant melanoma remains a highly lethal disease with an incidence that continues to rise.
  • Management of melanoma includes definitive local, regional and distant control.
  • There is substantial prospective and retrospective data to base the extent of both primary as well as adjuvant therapy.
  • A critical assessment of the available information pertaining to the adjuvant treatment of cutaneous melanoma is needed.
  • This review provides a critical assessment of the current data that is available to guide both primary resection as well as adjuvant therapy.
  • To date, current trials have shown little promise with nonspecific immunostimulants and cytotoxic chemotherapy.
  • In contrast, dose interferon-alpha2b has been shown to improve relapse-free survival and likely improves melanoma-specific survival as well.
  • Based on the available data, interferon-alpha2b remains the adjuvant therapy of choice for high-risk patients treated outside clinical trials, and the appropriate control arm for clinical trials evaluating new or modified adjuvant regimens.
  • [MeSH-major] Melanoma / pathology. Melanoma / therapy
  • [MeSH-minor] Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant / methods. Combined Modality Therapy. Humans. Interferon-alpha / therapeutic use. Lymphatic Metastasis / diagnosis. Radiotherapy, Adjuvant / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12633838.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interferon-alpha
  • [Number-of-references] 151
  •  go-up   go-down


78. Akimov MA, Gershanovich ML: [Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma]. Vopr Onkol; 2001;47(4):428-35
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma].
  • The effectiveness and side-effects of various chemotherapy (CT) regimens were compared in 157 patients (74 males and 80 females, aged 23-79) with disseminated skin melanoma (DSM).
  • Most cases had multiple metastases to the skin and subcutaneous fat tissue, regional lymph nodes (59-69%), lung (14-38%) and liver (13-36%); to other sites--82 (52%).
  • DTIC was employed as first-line treatment in 71%.
  • DBDT (cisplatin, DTIC, BCNU, tamoxifen) was used in 42 patients: as first-line--13 (31%), second-line--21 (50%) and third-line (following the first two regimens in cases refractory to treatment or those with response-based evidence of tumor progression)--8 (19%).
  • Similar results were recorded in the group where 69% were given CT as second- and third-line treatment.
  • Combined treatment with prospidin+ CCNU + BCNU seems to offer more advantage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11710284.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


79. Ichihashi N, Kitajima Y: Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. Br J Dermatol; 2001 Apr;144(4):745-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells.
  • BACKGROUND: Human malignant melanoma is notoriously resistant to chemotherapeutic agents.
  • Melanoma-derived cell lines are often markedly chemoresistant, suggesting that cellular mechanisms mediate generation of the multidrug resistance (MDR) phenotype.
  • This phenotype is often due to P-glycoprotein (Pgp) and the MDR-associated protein (MRP), which are drug transporter proteins associated with resistance to a broad spectrum of lipophilic drugs.
  • OBJECTIVES: To determine the relationships between the expression of the MDR gene MDR-1 (the product of which is Pgp) or the MRP gene, and clinical chemoresistance of malignant melanoma.
  • METHODS: We examined changes in the expression of MDR-1 and MRP genes at the mRNA level before and after chemotherapy by reverse transcription-polymerase chain reaction (RT-PCR) analysis using formalin-fixed, paraffin-embedded sections of 18 specimens taken from eight melanoma patients. mRNA expression of the MDR-1 and MRP gene-specific PCR products was quantitatively determined by densitometry and compared with that of an internal standard (beta-actin).
  • RESULTS: Five of seven primary melanomas were found to express the MRP gene to a certain extent even before chemotherapy.
  • After first and second courses of chemotherapy, six patients had an increased ratio of MRP mRNA to beta-actin mRNA compared with the prechemotherapy levels in the same patients.
  • None of the cases of melanoma expressed MDR-1.
  • CONCLUSIONS: These results suggest that a significant mRNA level of MRP gene was intrinsically present in malignant melanoma even before exposure to chemotherapeutic drugs and increased in its expression after chemotherapy, suggesting that MRP plays a part in increasing the chemoresistance of malignant melanoma during chemotherapy.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple. Melanoma / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic / drug effects. Humans. Multidrug Resistance-Associated Proteins. Neoplasm Proteins / metabolism. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298532.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


80. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z: Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res; 2000 Mar;6(3):863-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients.
  • Electrochemotherapy consists of chemotherapy followed by local application of electric pulses to the tumor to increase drug delivery into the cells.
  • The aim of this Phase II clinical study was to evaluate the antitumor effectiveness of electrochemotherapy using intratumoral cisplatin administration on cutaneous tumor nodules in malignant melanoma patients.
  • Four weeks after therapy, 78% objective responses were obtained in the electrochemotherapy group, and 38% objective responses were obtained in the cisplatin group.
  • Exposure of tumor nodules to electric pulses without cisplatin treatment had no effect on tumor growth.
  • Electrochemotherapy was well tolerated by all patients, and a good cosmetic effect was obtained, with only minimal scarring and a slight depigmentation of the skin.
  • Our results clearly demonstrate that electrochemotherapy with cisplatin is a highly effective approach for treatment of cutaneous malignant melanoma nodules.
  • The advantages of this therapy include its simplicity, the short duration of treatment sessions, low cisplatin doses, and insignificant side effects, as well as the fact that it can be done on an outpatient basis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Electric Stimulation Therapy. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741708.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Kudriavtsev DV, Kudriavtseva GT, Mardynskiĭ IuS: [Adjuvant chemotherapy as a component of complex treatment for skin melanoma]. Vopr Onkol; 2008;54(2):170-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
  • The efficacy of adjuvant chemotherapy as a component of complex treatment for skin melanoma and that of combined treatment alone was compared.
  • 502 patients were given combined treatment including intensive preoperative irradiation of primary foci (STD-19Gy, TTD-50 Gy, 5 days), their extended excision with or without lymphadenectomy and postoperative irradiation of regional lymph nodes.
  • Combined treatment was administered to 124 patients; additional adjuvant chemotherapy--5-fluorouracil, methotrexate, vincristine and cyclophosphamide (4 components)--200; neo- and adjuvant chemotherapy with cisplatin and doxorubicin (2 components)--106; cisplatin, doxorubicin and dacarbazine (3 components)--29.
  • Forty-three patients receiving individualized chemotherapy were not included in the study.
  • Five-year actuarial survival in combined treatment group was 69.2 +/- 4.4% (M +/- m), 4-component therapy--58.2 +/- 3.6%, 2 components--68.7 +/- 4.9% and 3 components--80.0 +/- 8.3% (p > 0.2); 5-year recurrence-free survival- 68.1 +/- 4.4%, 57.5 +/- 3.6%; 63.1 +/- 5.0% and 60.9 +/- 10.0% respectively.
  • No significant differences were found as far as a correlation was concerned between actuarial survival and recurrence-free one, on the one hand, and tumor stage, depth and extent of invasion, on the other.
  • Hence, no beneficial effect of said adjuvant chemotherapeutic measures on combined treatment for locally-advanced skin melanoma was found.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Melanoma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522165.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


82. Olver IN, Byrne MJ, Walpole E, Vorobiof D, Jacobs C, Maart K, Hewitt S, McAdam G, Pouget JC, Pinel MC: Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. Eur J Cancer; 2007 Aug;43(12):1829-32
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma.
  • This phase II study evaluated vinflunine in chemotherapy naive patients with metastatic melanoma.
  • The time to response was 1.4 months and duration was 6 months.
  • These results do not show activity at this dose and schedule for vinflunine in patients with chemotherapy naive metastatic melanoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Melanoma / drug therapy. Melanoma / secondary. Skin Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631996.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5BF646324K / vinflunine; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


83. Siegel R, Hauschild A, Kettelhack C, Kähler KC, Bembenek A, Schlag PM: Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol; 2007 Jun;33(5):627-32
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
  • AIM: Hepatic metastases from melanoma are associated with poor prognosis.
  • Systemic chemotherapy and biological treatments remain unsatisfactory.
  • This study investigated the impact of hepatic arterial chemotherapy in patients with ocular and cutaneous melanoma.
  • METHODS: In a retrospectively analysed observational study, 36 consecutive patients with hepatic metastases from ocular or cutaneous melanoma were assigned for surgical hepatic port-catheter implantation.
  • RESULTS: After port-catheter implantation 30/36 patients were finally treated (18 with ocular and 12 with cutaneous melanoma).
  • No significant difference in survival was observed for ocular versus cutaneous melanoma.
  • CONCLUSIONS: Hepatic arterial Fotemustine chemotherapy was well tolerated.
  • Meaningful response and survival rates were achieved in ocular as well as cutaneous melanoma.
  • Careful patient selection in consideration of extra-hepatic involvement is crucial for the effectiveness of this treatment.
  • Independent from the primary melanoma site, it is debatable if patients with highly elevated serum-LDH may benefit from this approach.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hepatic Artery. Liver Neoplasms / drug therapy. Melanoma / pathology. Nitrosourea Compounds / administration & dosage. Organophosphorus Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Eye Neoplasms / pathology. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Skin Neoplasms / pathology. Survival Analysis

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196362.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


84. Thivat E, Durando X, D'Incan M, Cure H, Mouret-Reynier MA, Madelmont JC, Souteyrand P, Chollet P: Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial. Anticancer Drugs; 2005 Oct;16(9):1003-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial.
  • Nitrosoureas possess some anti-tumor activity as a single agent in metastatic melanoma (MM).
  • In a phase II trial, we evaluated the anti-tumor effects of cystemustine chemotherapy, a new nitrosourea, as a second-line treatment.
  • Patients were required to have histologic evidence of disseminated MM and had failed in first-line chemotherapy.
  • Treatment comprised cystemustine given at a dose of 60 mg/m every 2 weeks by a 15-min infusion.
  • Median survival of responders and non-responders was 11 and 4 months, respectively.
  • We conclude that cystemustine at 60 mg/m is active in patients who progressed after one line of chemotherapy in advanced disease, and offers the possibility of complete responses and long durations of these responses.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Nitrosourea Compounds / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Nausea / chemically induced. Neoplasm Metastasis. Neutropenia / chemically induced. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162977.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 79955-36-5 / N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea
  •  go-up   go-down


85. Adedoyin OT, Johnson AW, Ojuawo AI, Afolayan EA, Adeniji KA: Malignant melanoma in a black child: predisposing precursors and management. J Natl Med Assoc; 2004 Oct;96(10):1368-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in a black child: predisposing precursors and management.
  • Malignant melanoma (MM) remains a pediatric rarity world-wide, but perhaps more so in black Africans.
  • A diagnosis of MM was confirmed by the subsequent histopathologic findings from the fine-needle aspirate and biopsy specimens.
  • Chemotherapy was initiated but was truncated shortly after by parent-pressured discharge.
  • Despite the rarity of MM in a tropical African setting where management options are few, the current case underscores the need for a high clinical index of diagnostic suspicion, an early pursuit of investigative confirmation, and prophylactic excision in children with the predisposing skin lesions, like congenital giant hairy nevus.
  • [MeSH-major] African Continental Ancestry Group / genetics. Dysplastic Nevus Syndrome / complications. Melanoma / etiology. Skin Neoplasms / complications
  • [MeSH-minor] Causality. Child, Preschool. Female. Humans. Lymph Nodes / pathology. Nigeria. Risk Factors. Skin Pigmentation / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 1999 May;63(5):293-8 [10349545.001]
  • [Cites] J Am Med Assoc. 1951 Nov 3;147(10):941-3 [14873600.001]
  • [Cites] Arch Dermatol. 1965 Feb;91:100-19 [14237589.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] Br J Dermatol. 1968 Jun;80(6):362-6 [5701724.001]
  • [Cites] Pediatrics. 1975 Feb;55(2):191-204 [1090894.001]
  • [Cites] Arch Dermatol. 1975 Dec;111(12):1658 [1200672.001]
  • [Cites] Br J Plast Surg. 1977 Oct;30(4):321-3 [588799.001]
  • [Cites] JAMA. 1978 Feb 20;239(8):744-6 [621895.001]
  • [Cites] JAMA. 1979 Dec 21;242(25):2795-9 [501893.001]
  • [Cites] J Am Acad Dermatol. 1979 Aug;1(2):123-30 [391836.001]
  • [Cites] J Am Acad Dermatol. 1979 Dec;1(6):503-5 [528699.001]
  • [Cites] Br J Dermatol. 1981 Mar;104(3):307-15 [7213564.001]
  • [Cites] Plast Reconstr Surg. 1981 Jun;67(6):782-90 [7243980.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1229-34 [6491702.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1720-3 [3651999.001]
  • [Cites] Important Adv Oncol. 1988;:217-57 [3042605.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):199-203 [2910418.001]
  • [Cites] J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):159-76 [2179292.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):438-41 [2009058.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1403-8 [2072144.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5074s-5079s [1884383.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):43-6 [7804976.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):656-62 [7845431.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):334-6 [7638982.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1833-45 [8625056.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 [8703684.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Surg. 1997 Jan;225(1):1-14 [8998115.001]
  • [Cites] Melanoma Res. 1997 Feb;7(1):63-8 [9067967.001]
  • [Cites] Curr Opin Pediatr. 1998 Aug;10(4):398-404 [9757365.001]
  • [Cites] J Dermatol Surg Oncol. 1978 Feb;4(2):153-8 [624799.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • (PMID = 15540891.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2568537
  •  go-up   go-down


86. Betschart C, von Orelli S, Mihic D, Fink D: [Primary malignant melanoma of the vagina--case report and review of the literature]. Gynakol Geburtshilfliche Rundsch; 2007;47(1):39-44
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the vagina--case report and review of the literature].
  • [Transliterated title] Primares malignes Melanom der Vagina--Fallbericht und Literaturubersicht.
  • The primary malignant melanoma of the vagina is a very rare tumor with less than 300 cases reported worldwide.
  • Metastatic melanomas of the vagina are even rarer and only 5 cases have been reported so far.
  • We describe the case of patient with a melanoma of the left side of the vagina with a tumor size of 6 cm and a tumor invasion of 2.5 cm.
  • At the time of diagnosis there were no signs of nodal metastases in the positron emission tomography.
  • In the literature, wide local excision with adjuvant radiotherapy is recommended, and radical surgery with adjuvant radiotherapy as second-line therapy.
  • To reduce the risk of metastases, we had planned an immunotherapy with interferon-alpha, which has been shown to improve relapse-free and overall survival in patients with high-risk cutaneous melanoma.
  • Unfortunately, the cancer was found to have heavily metastasized 6 months later; the patient therefore received a palliative chemotherapy with dacarbazine and thalidomide.
  • [MeSH-major] Melanoma / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Female. Humans. Middle Aged. Neoplasm Invasiveness. Palliative Care. Positron-Emission Tomography. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Vagina / pathology. Vagina / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17272935.001).
  • [ISSN] 1018-8843
  • [Journal-full-title] Gynäkologisch-geburtshilfliche Rundschau
  • [ISO-abbreviation] Gynakol Geburtshilfliche Rundsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 31
  •  go-up   go-down


87. Fujimoto M, Hiraga M, Kiyosawa T, Murakami T, Murata S, Ohtsuki M, Nakagawa H: Complete remission of metastatic clear cell sarcoma with DAV chemotherapy. Clin Exp Dermatol; 2003 Jan;28(1):22-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of metastatic clear cell sarcoma with DAV chemotherapy.
  • We report the first case of metastatic clear cell sarcoma with dramatic response to DAV treatment (DTIC + ACNU + VCR).
  • Clear cell sarcoma of tendons and aponeuroses, or malignant melanoma of soft parts, is a rare tumour that occurs predominantly in the extremities of young adults.
  • Although the importance of surgery has been established, the role of adjuvant chemotherapy has yet to be determined.
  • DAV should be considered as a first-line palliative treatment in disseminated disease as well as adjuvant therapy after surgery of primary clear cell sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma, Clear Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Dacarbazine / administration & dosage. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Nimustine / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12558622.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; DAV protocol
  •  go-up   go-down


88. Whitehead RP, Unger JM, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK, Southwest Oncology Group: A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study. Invest New Drugs; 2002 Feb;20(1):105-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
  • Malignant melanoma is rapidly increasing in the United States.
  • Metastatic disease responds poorly to currently available chemotherapy.
  • In this phase II trial, patients with no prior chemotherapy or immunotherapy for metastatic disease and performance status (SWOG) of 0-1, were treated with pyrazine diazohydroxide at a dose of 100 mg/m2/day by i.v. bolus injection over 5-15 minutes for 5 consecutive days every 6 weeks.
  • Pyrazine diazohydroxide by this dose and schedule has insufficient activity in the treatment of disseminated malignant melanoma to warrant further investigation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1988;21(4):269-73 [3370734.001]
  • [Cites] Cancer Treat Rev. 1990 Sep;17(2-3):109-17 [2272027.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):114-9 [8261430.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(6):425-9 [2311170.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):929-34 [9563886.001]
  • [Cites] Invest New Drugs. 1988 Apr;6(1):3-9 [3410664.001]
  • (PMID = 12003185.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04920; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA52386; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58686
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrazines; 103829-56-7 / pyrazine-2-diazohydroxide
  •  go-up   go-down


89. Luo D, Xia H: [Clinical and pathological characteristics of head and neck malignant melanoma]. Zhonghua Zhong Liu Za Zhi; 2001 May;23(3):256-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological characteristics of head and neck malignant melanoma].
  • OBJECTIVE: To investigate the clinical and pathological characteristics of head and neck malignant melanoma.
  • METHODS: Sixty-eight cases of head and neck malignant melanoma were reviewed.
  • There were 33 patients with melanoma in the nasal cavity and oral cavity, 35 patients with melanoma in the skin.
  • Immunohistochemical studies helped diagnosis as all of the 42 melanoma specimens were posture for S-100 and 90.5% positive for HMB45.
  • In 52 of the 68 cases, the tumor was excised surgically, with additional radiotherapy in 13 cases or chemotherapy in 21 cases.
  • In 56 patients followed-up, 12 survived for 5 years, including 9 cases of skin melanoma and 3 cases of nasal and oral melanoma.
  • CONCLUSION: The histo-pathological features of malignant melanoma vary significantly.
  • Immunohistochemical staining helps diagnosis and differential diagnosis.
  • The prognosis of malignant melanoma in nasal cavity and oral cavity is poor as compared to that in the skin of head and neck region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasm Proteins / analysis. S100 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Male. Melanoma-Specific Antigens. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783102.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


90. Fujii K, Goto A, Matsunaga Y, Hasegawa Y, Sukawa Y, Suzuki K, Yonezawa K, Abe T, Itoh A, Shinomura Y, Iimura Y, Hasegawa N, Nakamura H, Yoshida Y: [Primary malignant melanoma of the esophagus--detection of circulating tumor cells]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1539-43
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the esophagus--detection of circulating tumor cells].
  • Primary malignant melanoma of esophagus (PMME) is a rare tumor; therefore, the prognostic factors, predictive factors, and difference in biological behaviors of cutaneous melanoma and primary esophageal squamous cell carcinoma remain uncertain.
  • Although we did not adopt a standard therapeutic strategy, we performed surgical resection, chemotherapy, immunotherapy, and radiotherapy either alone or in combination; all procedures resulted in poor outcomes.
  • A 67-year-old woman presented with a swallowing disorder.
  • An esophagogastroduodenoscopy was performed, leading to diagnosis of PMME.
  • According to the Japanese Classification of Esophageal Cancer, the pathological stage was T1b, ly0, v0, N0, M0, stage I .
  • After subtotal esophagectomy, adjuvant chemotherapy was performed, but the malignant melanoma relapsed in the mediastinum and the patient died 10 months after diagnosis.
  • We serially monitored the patient using several new modalities, including PET/CT, metabolites of melanin: 5-S-CD, and circulating tumor cells (CTCs) by reverse transcription-polymerase chain reaction to identify the melanoma-specific gene.
  • [MeSH-major] Esophageal Neoplasms / pathology. Melanoma / pathology. Neoplastic Cells, Circulating
  • [MeSH-minor] Aged. Biopsy. Fatal Outcome. Female. Gene Expression Regulation, Neoplastic. Humans. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716882.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Esmaeli B, Wang B, Deavers M, Gillenwater A, Goepfert H, Diaz E, Eicher S: Prognostic factors for survival in malignant melanoma of the eyelid skin. Ophthal Plast Reconstr Surg; 2000 Jul;16(4):250-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in malignant melanoma of the eyelid skin.
  • PURPOSE: This study aimed to determine the prognostic factors for survival and disease-free interval for malignant melanoma of the eyelid skin.
  • Twenty-four patients with eyelid skin melanoma were identified through a search of the tumor registry at M. D.
  • Anderson Cancer Center.
  • Primary treatment in all cases entailed wide local excision of the tumor.
  • Patients in whom regional lymph node metastasis developed underwent parotidectomy or neck dissection, with or without adjuvant chemotherapy or external beam radiation.
  • Survival analysis in terms of disease-free survival and recurrence-free survival was performed using age, sex, location of tumor (upper lid, lower lid, or both), histologic type of melanoma, Breslow thickness, and Clark's level as independent variables for survival.
  • RESULTS: Age, sex, location, and the histologic type of tumor were not significant prognostic indicators for survival in this cohort.
  • CONCLUSION: Clark's level > or = IV or Breslow thickness > or = 1.5 mm are poor prognostic indicators for malignant melanomas of the eyelid skin.
  • [MeSH-major] Eyelid Neoplasms / mortality. Melanoma / mortality. Skin Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923972.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


92. Mu XC, Tran TA, Ross JS, Carlson JA: Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma. J Cutan Pathol; 2000 May;27(5):242-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
  • Malignant melanoma (MM) is considered to be a chemotherapy-refractory tumor.
  • New anti-cancer drugs (e.g. etoposide) that target DNA topoisomerases (e.g. topoisomerase II-alpha (topo IIalpha)) show activity against a wide variety of solid tumors.
  • The rate of topo IIalpha labeling in dysplastic melanocytic nevi, radial growth phase MM, vertical growth phase MM and metastatic MM revealed significant differences amongst groups and a positive covariance with advancing stage (means: 0.3, 0.5, 5, and 8 '+' cells/hpf, respectively; r=0.3, all p < or = 0.02).
  • These findings indicate topo IIalpha as a potential therapeutic target and marker for MM.
  • Immunohistochemical analysis of disseminated MM may allow for correlation with clinical response and enable selection of candidates sensitive for specific chemotherapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. Isoenzymes / metabolism. Melanoma / enzymology. Nevus, Pigmented / enzymology. Skin Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10847549.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Isoenzymes; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


93. Crosby T, Fish R, Coles B, Mason MD: Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev; 2000;(2):CD001215
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatments for metastatic cutaneous melanoma.
  • BACKGROUND: Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing.
  • Few lasting remissions are achieved and the therapeutic aim remains one of palliation.
  • OBJECTIVES: To review the benefits from the use of systemic therapies in metastatic cutaneous melanoma compared to best supportive care/placebo, and to establish whether a 'standard' therapy exists which is superior to other treatments.
  • Cancer registries and trialists were also contacted.
  • SELECTION CRITERIA: Randomised controlled trials of adults with histologically proven metastatic cutaneous melanoma in which systemic anti-cancer therapy was compared with placebo or supportive care.
  • MAIN RESULTS: No randomised controlled trials were found comparing a systemic therapy with placebo or best supportive care in metastatic cutaneous melanoma.
  • REVIEWER'S CONCLUSIONS: There is no evidence from randomised controlled clinical trials to show superiority of systemic therapy over best supportive care / placebo in the treatment of malignant cutaneous melanoma.
  • Given that patients with metastatic melanoma frequently receive systemic therapy, it is our pragmatic view that a future systematic review could compare any systemic treatment, or combination of treatments, to single agent dacarbazine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Melanoma / secondary. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2012 Dec;37(8):924-5 [23050590.001]
  • (PMID = 10796759.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 0
  •  go-up   go-down


94. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A; 2007 Jun 26;104(26):11014-9
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
  • Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clinical use.
  • However, Top2-based chemotherapy has been associated with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients.
  • In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is found to be significantly higher in TOP2beta(+) than in skin-specific top2beta-knockout mice.
  • These results point to the importance of developing Top2alpha-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Apr 1;87(7):2649-58 [8639880.001]
  • [Cites] Biochim Biophys Acta. 1992 Aug 17;1132(1):43-8 [1380833.001]
  • [Cites] Mol Pharmacol. 1996 Dec;50(6):1463-71 [8967966.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4070-9 [9199342.001]
  • [Cites] Mol Pharmacol. 1998 Jul;54(1):78-85 [9658192.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3793-803 [9808573.001]
  • [Cites] Annu Rev Genet. 1998;32:495-519 [9928489.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1912-22 [8634439.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2568-76 [10509651.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72 [16101488.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2289-95 [16193084.001]
  • [Cites] Cell. 1992 Nov 13;71(4):691-700 [1423624.001]
  • [Cites] Biochim Biophys Acta. 1993 Mar 20;1172(3):283-91 [8383537.001]
  • [Cites] Nat Genet. 1992 Oct;2(2):113-8 [1303259.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3197-203 [8389614.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4489-92 [8402620.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2327-30 [8162575.001]
  • [Cites] Neurosci Res. 1994 Feb;19(1):51-7 [8008235.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):467-70 [7984241.001]
  • [Cites] Leukemia. 1995 Aug;9(8):1305-12 [7643617.001]
  • [Cites] Oncol Res. 1995;7(2):103-11 [7579726.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8975-9 [16982737.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):7929-41 [16923961.001]
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):35997-6003 [16973621.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25231-8 [10940316.001]
  • [Cites] Development. 2000 Nov;127(22):4775-85 [11044393.001]
  • [Cites] Biochemistry. 2001 Feb 6;40(5):1159-70 [11170441.001]
  • [Cites] J Biol Chem. 2001 Feb 23;276(8):5769-78 [11106659.001]
  • [Cites] J Comp Neurol. 2001 Mar 5;431(2):228-39 [11170002.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:53-77 [11264450.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):525-35 [11340607.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4550-5 [11389089.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31590-5 [11406628.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40652-8 [11546768.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1909-12 [11877259.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1377-81 [12649202.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5205-10 [12692309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7123-8 [12773624.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):257-65 [15334549.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 May;81(9):2616-20 [6326134.001]
  • [Cites] Science. 1984 Oct 26;226(4673):466-8 [6093249.001]
  • [Cites] Cell. 1985 Jun;41(2):553-63 [2985283.001]
  • [Cites] Cell. 1987 Sep 11;50(6):917-25 [3040264.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1671-9 [10861294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177-81 [2845399.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6919-24 [1698546.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Cancer Res. 1991 Dec 15;51(24):6712-4 [1835902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5068-72 [1375756.001]
  • [Cites] Histochem Cell Biol. 1996 Apr;105(4):261-7 [9072183.001]
  • (PMID = 17578914.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM024544; United States / NCI NIH HHS / CA / CA102463; United States / NCI NIH HHS / CA / R01 CA102463; United States / NIGMS NIH HHS / GM / R37 GM024544; United States / NIGMS NIH HHS / GM / GM24544
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoenzymes; 0 / Protease Inhibitors; 0 / Topoisomerase II Inhibitors; 6PLQ3CP4P3 / Etoposide; EC 5.99.1.3 / DNA Topoisomerases, Type II
  • [Other-IDs] NLM/ PMC1904155
  •  go-up   go-down


95. Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic M: Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst; 2003 Feb 19;95(4):308-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma.
  • BACKGROUND: The mechanism underlying the role of UV light exposure from sunlight in the etiology of cutaneous malignant melanoma (CMM) is unclear.
  • Patients with xeroderma pigmentosum, a disease characterized by severe sensitivity to UV radiation and a defect in nucleotide excision repair, have a high incidence of CMM, which suggests that DNA repair capacity (DRC) plays a role in sunlight-induced CMM in the general population as well.
  • METHODS: We conducted a hospital-based case-control study of DRC and CMM among 312 non-Hispanic white CMM patients who had no prior chemotherapy or radiation therapy, and 324 cancer-free control subjects who were frequency-matched to case patients on age, sex, and ethnicity.
  • DRC that was at or below the median value (i.e., 9.4%) in control subjects was associated with increased risk for CMM after adjustment for age, sex, and other covariates (odds ratio [OR] = 2.02, 95% confidence interval [CI] = 1.45 to 2.82).
  • We observed a dose-response relationship between decreased DRC and increased risk of CMM (P(trend)<.001).
  • Patients with tumors on sun-exposed skin had statistically significantly lower DRC than patients with tumors on unexposed skin (8.2 +/- 3.3% versus 9.5 +/- 3.5%; P =.004).
  • CONCLUSIONS: Reduced DRC is an independent risk factor for CMM and may contribute to susceptibility to sunlight-induced CMM among the general population.
  • [MeSH-major] DNA Damage. DNA Repair. Melanoma / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12591987.001).
  • [ISSN] 0027-8874
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES 11740; United States / NCI NIH HHS / CA / R29 CA 70334
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


96. Freeman KP, Hahn KA, Harris FD, King GK: Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). J Vet Intern Med; 2003 Jan-Feb;17(1):96-101
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997).
  • This retrospective study in 39 dogs with incompletely resected oral melanoma examined the efficacy of hypofractionated radiation therapy and platinum-containing chemotherapy.
  • All dogs were completely staged, with the majority of dogs classified as stage 1.
  • Dogs received 6 weekly fractions of 6-gray (Gy) megavoltage irradiation with a cobalt-60 unit or a 4-MeV (megaelectron volts) linear accelerator.
  • Dogs received cisplatin (10-30 mg/m2 IV) or carboplatin (90 mg/m2 IV) chemotherapy 60 minutes before radiation delivery.
  • Durations of local control, metastasis-free survival time, and overall survival time were recorded.
  • By the Kaplan-Meier method, 15% of the dogs had local recurrence within a median time of 139 days.
  • Fifty-one percent of the dogs developed metastatic disease within a median time of 311 days (range, 24-2, 163 days).
  • Median survival time for all 39 dogs was 363 days.
  • The combined use of chemotherapy and radiation therapy in this protocol provided local control consistent with previous studies.
  • Low-dose chemotherapy was used with the intent of enhancing radiation therapy for the local control of an incompletely excised tumor.
  • Survival times were longer than previously reported for dogs with oral malignant melanoma.
  • Additional studies are required to determine whether these results were due to the effects of chemotherapy on microscopic disease or the enhanced local control provided by chemoradiation therapy.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12564733.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


97. Najar HM, Dutz JP: Topical CpG enhances the response of murine malignant melanoma to dacarbazine. J Invest Dermatol; 2008 Sep;128(9):2204-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
  • Malignant melanoma is a potentially fatal skin cancer that is increasing in incidence.
  • We describe a chemoimmunotherapy protocol for cutaneous melanoma that combines the administration of DTIC with the topical application of CpG oligodinucleotide (ODN).
  • Subcutaneous B16 melanoma tumors in C57BL/6 mice were treated with intraperitoneal injections of DTIC followed by the topical application of CpG-ODN over the tumors.
  • This therapeutic approach abrogated the growth of established tumors and significantly enhanced survival.
  • By enhancing both tumor cell death and local immune activation, DTIC/topical CpG chemoimmunotherapy induced an effective T-cell-dependent host-immune response against melanoma.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / therapeutic use. Melanoma / drug therapy. Oligodeoxyribonucleotides / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Animals. Apoptosis / drug effects. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / pathology. Cell Line, Tumor. Disease Models, Animal. Drug Therapy, Combination. Injections, Intraperitoneal. Mice. Mice, Inbred C57BL. T-Lymphocytes, Cytotoxic / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18368132.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents, Alkylating; 0 / CPG-oligonucleotide; 0 / Oligodeoxyribonucleotides; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


98. Kubo H, Ashida A, Matsumoto K, Kageshita T, Yamamoto A, Saida T: Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res; 2008 Jul;300(6):297-301
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells.
  • We investigated the anti-tumor effect of human interferon-beta (HuIFN-beta) against malignant melanoma.
  • In vitro study revealed that HuIFN-beta not only inhibited proliferation of melanoma cells (seven cell lines: MM-AN, MM-BP, MM-LH, MM-RU, PM-WK, RPM-EP, RPM-MC) but also induced apoptosis in a dose dependent fashion, though the sensitivity to HuIFN-beta was different among cell lines.
  • In addition, we administered HuIFN-beta into cutaneous metastatic lesions of melanoma and evaluated clinical and histopathological effects.
  • Although the size of the metastatic cutaneous lesion did not change by the intralesional injection of HuIFN-beta, histopathological examination revealed apoptotic changes of melanoma cells along with dense lymphohistiocytic infiltration.
  • The present study confirmed direct and indirect inhibitory effects of HuIFN-beta on human melanoma cells and suggests that local higher concentration of HuIFN-beta is needed to eradicate melanoma lesions.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Immunotherapy. Interferon-beta / pharmacology. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Drug. Down-Regulation. Humans. Injections, Intralesional. Neoplasm Metastasis. Vaccination

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324409.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta
  •  go-up   go-down


99. Rivière F, Bonnichon-Py A, Le Floch H, Salles Y, Staub E, Mairovitz A, Foehrenbach H, Margery J, Pons F, Marotel C, Vaylet F: [Pulmonary malignant melanoma: primary or metastatic?]. Rev Mal Respir; 2010;27(1):88-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary malignant melanoma: primary or metastatic?].
  • [Transliterated title] Mélanome malin pulmonaire: primitif ou métastase ?
  • Primary pulmonary malignant melanoma is rare (0.01% of pulmonary cancers); only 25 cases are published in the literature.
  • The diagnosis of primary pulmonary malignant melanoma is controversial, the pathogenesis is unknown and a pulmonary metastasis from a mucocutaneous melanoma is the main differential diagnosis.
  • The diagnosis is based on the strict application of the Jensen criteria published in 1967.
  • We report the case of an asymptomatic 82-year-old man presenting with a fortuitously discovered primary pulmonary malignant melanoma according to the Jensen criteria and treated by lobectomy (cT1N0M0).
  • Surgery seems to be the gold standard treatment on account of the poor sensitivity of melanoma to chemotherapy and radiotherapy.
  • This observation raises the question of (18)FDG CT-PET in this situation, particularly of the whole body, by extrapolation from the recommendations in mucocutaneous melanoma.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / secondary. Melanoma / pathology. Melanoma / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Fluorodeoxyglucose F18. Humans. Image Processing, Computer-Assisted. Lung / pathology. Lymph Nodes / pathology. Male. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146959.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


100. Eisen T, Thomas J, Miller WH Jr, Gore M, Wolter P, Kavan P, Martín JA, Lardelli P: Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res; 2009 Jun;19(3):185-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
  • The objective of this study was to evaluate the antitumor activity and safety profile of 5 mg/m2 plitidepsin administered as a 3-h continuous intravenous infusion every 2 weeks to patients with advanced malignant melanoma who relapsed or progressed after one line of systemic therapy.
  • Objective response rate (primary efficacy endpoint) was evaluated according to Response Evaluation Criteria In Solid Tumors and toxicity was assessed using National Cancer Institute -Common Toxicity Criteria Version 2.0.
  • Of 39 enrolled patients (median age: 53 years), 37 patients were treated who received a total of 167 treatment cycles (median: 3 cycles per patient; range: 1-32).
  • All patients had received prior systemic therapy with a median of one line per patient (range: 1-6 lines).
  • Of the 35 evaluable patients, two dacarbazine-resistant patients (5.7%) with metastatic cutaneous melanoma achieved partial responses.
  • Six patients (16.2%) had the following treatment-related grade 3/4 adverse events: myalgia (n = 3), injection-site reaction (n = 2), hypersensitivity, hypotension, and fatigue (n = 1 each).
  • Plitidepsin showed a minor degree of antitumor activity in patients with refractory advanced malignant melanoma.
  • [MeSH-major] Depsipeptides / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19436178.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Depsipeptides; Y76ID234HW / aplidine
  •  go-up   go-down






Advertisement